{
  "name" : "dacemirror.sci-hub.se_journal-article_0c000642be47af52b07d90bbc2a1cef3_ovais2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages",
    "authors" : [ "Muhammad Ovais", "Mengyu Guo", "Chunying Chen" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "REVIEW\n1808303 (1 of 26) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim\nwww.advmat.de\nTailoring Nanomaterials for Targeting Tumor-Associated Macrophages\nMuhammad Ovais, Mengyu Guo, and Chunying Chen*\nDOI: 10.1002/adma.201808303\ncancer immunotherapies has taken several years to develop, but key advancements in the basics of cancer immunology and translational immunotherapy have now resulted in treatments having noteworthy therapeutic effects in clinical trials.[2] These treatments include the injection of autologous, tumor-directed T cells, as a form of adoptive cell therapy (ACT), checkpoint blockade, and antibodies blocking the inhibitory receptors cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1, or its counter-receptors PD-L1/PDL2).[3] Interestingly, ACT therapy can elicit a thorough eradication of detectable tumor burden in patients with advanced metastatic melanoma or hematologic cancer, with long-term responses. In 20% of advanced melanoma patients, a fully humanized anti-CTLA-4 antibody (ipilimumab) produced a complete response lasting for a decade.[4] In a variety of cancers (lung, prostate, breast, ovarian, and head and\nneck and colorectal) treatment with PD-1 blocking antibodies demonstrated potent responses.[5] The combination therapies of anti-CTLA-4 and anti-PD1 has led to even more significant responses in melanoma patients due to the complementary modes of action of the two target proteins.[6]\nSufficient activation of the immune system by a cancer immunotherapy to affect a potent response is a slow process, especially in patients with advanced cancer.[7] A patient’s specific immune status, genetics, tumor type, and environmental exposure can all affect the outcome of cancer immunotherapy.[8] Nanoparticles, due to their diverse physical and chemical properties, can be utilized as potential immunomodulating agents.[10] However, the specific toxicity associated with immunotherapies, along with the low response rate, are two important obstacles to consider in the preclinical and clinical development of cancer immuno-nanomedicines.[9]\nMyeloid-derived macrophages and tissue-resident macrophages, collectively known as tumor-associated macrophages (TAMs), are present in the tumor microenvironment (TME).[11] Upon interaction with a tumor, TAMs can become immunosuppressed and behave as regenerative macrophages. The origin (either recruitment from peripheral sites outside the CNS or tissue-resident cell invasion) composition and phenotypic evolution of TAMs during tumorigenesis are currently under intense investigation.[12] Based on the cellular context, TAMs can exhibit tumoricidal M1 or regenerative M2 phenotypic activation states;\nAdvances in the field of nanotechnology together with an increase understanding of tumor immunology have paved the way for the development of more personalized cancer immuno-nanomedicines. Nanovehicles, due to their specific physicochemical properties, are emerging as key translational moieties in tackling tumor-promoting, M2-like tumor-associated macrophages (TAMs). Cancer immunonanomedicines target TAMs primarily by blocking M2-like TAM survival or affecting their signaling cascades, restricting macrophage recruitment to tumors and re-educating tumor-promoting M2-like TAMs to the tumoricidal, M1-like phenotype. Here, the TAM effector mechanisms and strategies for targeting TAMs are summarized, followed by a focus on the mechanistic considerations in the development of novel immuno-nanomedicines. Furthermore, imaging TAMs with nanoparticles so as to forecast a patient’s clinical outcome, describing treatment options, and observing therapy responses is also discussed. At present, strategies that target TAMs are being investigated not only at the basic research level but also in early clinical trials. The significance of TAM-targeting biomaterials is highlighted, with the goal of facilitating future clinical translation.\nTumor-Associated Macrophages\nM. Ovais, M. Guo, Prof. C. Chen CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology (NCNST) Beijing 100190, China E-mail: chenchy@nanoctr.cn M. Ovais, M. Guo, Prof. C. Chen School of Nanoscience and Technology College of Materials Sciences and Opto-Electronic Technology University of Chinese Academy of Sciences Beijing 100049, China\nThe ORCID identification number(s) for the author(s) of this article can be found under https://doi.org/10.1002/adma.201808303."
    }, {
      "heading" : "1. Introduction",
      "text" : "Immunotherapies modulate the immune system and strengthen its natural role in host protection, maintaining the immune system’s fundamental features of potency, specificity, and memory. Recent clinical developments in cancer immunotherapy have opened new avenues in immune-mediated tumor eradication by stimulating the host’s immune system and improving the lives of end stage patients.[1] Hampered by toxicity issues and low efficacy, the clinical translation of\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (2 of 26)\nM2 TAMs are immunosuppressed and promote tumor invasion. As an alternative approach to directly targeting tumor cells, modulating TAMs is emerging as a viable strategy in the treatment of solid tumors. This method of tumor treatment is currently being investigated in both basic research and early clinical trial contexts.[13] Tumor angiogenesis, survival, and growth are all promoted by TAMs upon immunosuppression of the adaptive immune response in early tumorigenesis. Interestingly, TAMs, functioning upstream of T cell responses, present a more promising target over therapies that purely modulate T cells, such as adoptive transfer of tumor-specific T cells or T cell checkpoint inhibitors. A recent study showed that the targeting of macrophages via PD1-inhibition, in a T cell independent fashion, elicited an upstream, macrophage-enhancement of the adaptive immune response.[14]\nNovel strategies aimed at modulating the TME have resulted in various translational research approaches targeting TAMs.[15] With an eye toward current advances in the field of cancer immuno-nanomedicine, we summarize the effective mechanisms and TAM-targeting strategies for TAMs (Sections 2 and 3) along with key focus on novel approaches in the design of biomaterials for TAMs targeting (Section 4), and advances in imaging TAMs via nanoparticles (Section 5). The study of cancer immune-nanomedicine is an interface that bridges the different fields of nanotechnology, oncology, and immunology. From our understanding of immune system evasion, researchers have developed methods to activate the immune system using nanoparticles (NPs) and effectively eradicate tumors. The most recent developments in the specific enhancement of antitumor immune responses by targeting TAMs with biomaterials have shown significant promise and potential clinical relevance (Scheme 1)."
    }, {
      "heading" : "2. Cancer Immuno-Nanomedicine: Promising Targets",
      "text" : "During tumor progression, the immune system is shaped in two divergent ways in a process known as immunoediting. On the one hand, the immune system protects the host against the cancer, while, on the other hand, tumor immunogenicity becomes conditioned in three phases: elimination, equilibrium, and escape.[7b,16] Due to mechanical disruption of healthy tissues the tumor cells activate the innate immune system in the elimination phase. In the tumor cells, angiostatic chemokine expression and cell death are caused by the secretion of IFNgamma from macrophages and dendritic cells (DCs).[17] The dendritic cells and macrophages engulf the dying cancer cells’ antigens and proteins, followed by delivery of these materials to the draining lymph nodes (DLNs) for activation of CD4+ T cells and, in turn, CD8+ T cells. Via either the release of cytotoxic proteins or the Fas/FasL pathway, the tumor-associated antigen (TAA)-activated T cells circulate to the tumor microenvironment and induce cell death. A feedback loop of additional IFN-gamma and IL-12 secretion leads to an IFN-gamma-induced proinflammatory tumor microenvironment, which enhances tumor cell apoptosis. Cancer cells that are genetically mutated and immunoresistant survive the elimination phase and transit to equilibrium, in which a tumor cell quiescent phase is maintained by a balance between immune attack and cancer cell proliferation, preventing outgrowth of the tumor.[18] The immunosuppressive tumor microenvironment is created by the resistant cancer cells that have acquired mutations, while immune-sensitive\nMengyu Guo received her bachelor’s degree (2015) in chemical biology from Sichuan Agriculture University, China. Currently, she is a Ph.D. candidate in Professor Chen’s group at the CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and\nTechnology of China. Her research work is focused on the development of nanomaterials for targeted tumor immunotherapy and drug delivery applications.\nChunying Chen is a principal investigator at the CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in the National Center for Nanoscience and Technology of China. She received her bachelor’s degree in chemistry (1991) and obtained her Ph.D. degree in biomedical engineering from Huazhong University\nof Science and Technology of China in 1996. Her research interests include potential toxicity of nanoparticles, therapies for malignant tumors using theranostic nanomedicine systems, and vaccine nanoadjuvants using nanomaterials.\nMuhammad Ovais obtained his B.S. degree in biotechnology from the University of Peshawar in 2015 and his M.S. degree in 2017 from Quaid-i-Azam University. In the latter year he joined Professor Chen’s group as a Ph.D. candidate at the CAS Key Laboratory for Biomedical Effects of Nanomaterials\nand Nanosafety, National Center for Nanoscience and Technology of China. His research interest lies in the development of multifunctional nanodelivery systems for targeted cancer immunotherapy.\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (3 of 26)\ntumor cells are cleared by the immune system. A decrease in TAA presentation and loss of major histocompatibility complex (MHC) class I expression are two major escape mechanisms acquired by the resistant cancer cells. Additionally, cancer cells can inhibit costimulatory molecules, such as CTLA-4, PD-1, and PD-L1, and produce the suppressive cytokines, TGF-beta and IL-10. In the survival and expansion of the tumor, regulatory T cells, tumor-associated macrophages, and myeloid-derived dendritic cells play vital roles.[19]"
    }, {
      "heading" : "2.1. Immune Cascades and the Underlying Targets",
      "text" : "Although the past decade has seen cancer nanomedicine research focus on the targeting of tumor or stromal cells, novel cancer immunotherapies have recently opened new avenues in the design of nanoparticles as potent immune-stimulating agents with antitumor responses.[20] While cytotoxic agents are required at high concentrations for the eradication of tumor cells, by contrast, the activation of immune cells can elicit potent immune responses, given the intrinsic nature of these cells to proliferate and expand. Interestingly, disease relapse can\nbe prevented via the unique memory exhibited by the adaptive immune responses generated against tumors.\nThe targeted delivery of immunostimulatory agents via nanoparticles is an emerging paradigm to modulate specific immune-activation/inhibition pathways for enhanced antitumor effects. In contrast to conventional therapies, cancer immunotherapies specifically detect, recognize, and destroy malignant cells by boosting the host’s own immune system.[21] Immunity against a tumor is the result of complex interactions between the innate and adaptive immune system, where nonclonal receptors, such as Toll-like receptors (TLRs), lectins, or nucleotide-binding oligomerization domain-like receptors (NLRs), are used by innate immune cells to identity foreign pathogens. In the case of adaptive immune system cells (T and B cells), non-self antigens are specifically recognized by clonal receptors.[22] T cells in the lymph nodes are presented with antigens via antigen-presenting cells (APCs), such as DCs and macrophages, which connect the innate and adaptive immune systems. Naive T cells are primed in the process and become cytotoxic to the tumor cells. These cells also have a specific memory. DCs and macrophages are recruited by chemoattractants (lipid lysophosphatidylcholine, sphingosine\nAdv. Mater. 2019, 1808303\nScheme 1. The nanomaterial–biology (nano–bio) interface for targeting TAM signaling pathways, leading to inhibition of recruitment, interference with survival, and cellular re-education.\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (4 of 26)\n1-phosphate, and CX3CL1) released by the dying tumor cells.[23] Calreticulin, a membrane-bound receptor expressed by tumor cells, is recognized by phagocytes that results in its uptake.[24] DCs and macrophages express Fc receptors, which can result in antibody-mediated uptake through interaction with specific receptors on the tumor cells, while NK cells also mediate antibody-dependent, cell-mediated toxicity.[25]\nTumor cells can evade the innate immune system in several ways: one such mechanism is the expression of CD47 on the cancer cell surface, resulting in phagocytic cytoskeletal remodeling upon interaction with signal regulatory protein alpha (SIRPα) protein, ultimately resulting in a “do not eat me” signal.[26] In the case of escape from adaptive immunity, tumor cells inhibit T cell proliferation via overexpression of programmed death-ligand 1 (PD-L1) or PD-L2 immune-suppressive ligands.[27] Likewise, the function of T cells is also suppressed upon interaction of galectin-9 and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3).[28] Cancer cells also evade detection by T cells by downregulating the expression of major histocompatibility complex proteins (MHC).[29] Novel therapies may reprogram T cells so that little MHC recognition is required or MHC expression in cancer cells is enhanced for effective detection. Regulatory T cells or myeloid-derived suppressive cells can also be recruited by the cancer cells to promote immune suppression.[30] Furthermore, tumor cells can also reprogram the TME and turn immune effector cells into immunosuppressants, as evident from the conversion of TAMs from a proinflammatory to an antiinflammatory phenotype.[31] Immune evasion by tumor cells is further promoted by these regulatory cells via production of immune-suppressive cytokines (interleukin (IL)-10 and TGF-β), expression of immune checkpoint proteins (cytotoxic T-lymphocyte-associated protein 4, CTLA-4), and downregulation of the immune-activating signals, OX40L and CD40.[32]\nTargeting the immunosuppressive mechanisms exhibited by cancer cells holds great promise in designing nanomedicines for immuno-oncology. Considering the complexity of immuneregulatory processes it becomes vital to target several molecular pathways via a simultaneous delivery of different immunestimulatory or anti-immune-inhibitory agents. Nanomedicine, with its unique targeting and protected transport features, holds great promise for accomplishing this multipronged therapeutic strategy. Nanoparticles can prevent the degradation of nucleic acids or interference with nucleic acid delivery for reprogramming APCs or T cells.[33] Interestingly, nanoparticles, due to their intrinsic properties, can be taken up by scavenging macrophages and accumulate in the lymphoid tissues.[34] For conventional nanomedicines, this accumulation is considered unfavorable due to associated toxicity, but in the context of immune nanomedicines it may positively modulate the systemic immune activation and properly engage the immune system."
    }, {
      "heading" : "2.2. Nanomedicine for Immuno-Oncology: Emerging Paradigms",
      "text" : "The fundamental nanomedicine designs were based on targeting cytotoxic drugs to tumor cells, preventing accumulation in normal tissues. Even though nanomedicines have shown success in modifying the pharmacokinetics of conventional\ndrugs, the suboptimal delivery of nanoparticles and tumortargeting specificity have remained substantial challenges. As evident from one of the recently published meta-analyses on cancer nanomedicine articles, only 0.7% of injected nanoparticle doses reach the intended tumor, clearly highlighting the serious hindrance in the clinical translation of nanoparticle therapeutics.[35] Key advances in cancer immunotherapies have opened new paradigms for the development of cancer immuno-nanomedicines. The success of immune-checkpoint blockers (anti-CTLA-4 or anti-PD-1/PD-L1 antibodies) demonstrates that targeting tumor cells may not be essential in the design of effective, future therapies. With these developments in mind, research efforts have begun to turn toward the design of nanomedicines that, instead of delivering cytotoxic drugs to the tumor, modulate the immune system to recognize and kill cancer cells.[13a] Due to antigen-specific responses, immune cells possess a targeted cytotoxicity and have the ability to penetrate the blood–brain and the blood–testis barriers. The risk of tumor recurrence is also mitigated via immune memory, which continuously produces effector T cells once activated.\nResearchers have recently described various strategies for cancer cell targeting through the design of immune-based nanomedicines. Nanoparticles delivering antigens along with viral proteins have been used as cancer vaccines, while viral proteins’ immunogenic nature can be delivered to DCs or macrophages by nanoparticles.[36] Even with some success in animal models, these methods have limitations, such as the generation of an immune response against tumor cells that express a particular antigen and no other tumoral cells that are negative for the targeted protein. Furthermore, there is also the risk of autoimmune response generation due to immune stimulation by viral nanoparticles cross-reacting with self-epitopes. Genetic and transcriptional manipulation can be affected in immune effector cells with the help of nanoparticles specifically designed to deliver nucleic acids. Potent antitumor responses can be achieved via the delivery of RNA to DCs to enhance the expression of tumor-specific antigen presentation and T cell priming.[33a] Changes in the tumor immune microenvironment via nanoparticle-delivered siRNA can downregulate genes in monocytes to result in strong antitumor effects. With the emergence of novel genome-editing tools, nanoparticles can act as delivery platforms to engineering immune cells with precise gene editing, ultimately leading to tumor eradication.[37] Interestingly, in contrast to conventional nanomedicines, pathophysiological barriers present in the TME of solid tumors are not an obstacle for nanoparticles which target immune cells in the lymphoid tissues. Interestingly, nanoparticles can be designed to target phagocytes in the liver or spleen by simply accumulating in those organs.\nTargeting specific immune cell subsets or delivering nanoparticles to different lymphoid tissues is a challenging task for cancer nanomedicine. Nanomedicines, in addition to acting as delivery vehicles for antigens or as immune-modulatory agents, can also directly activate T cells and promote antigen recognition. T cells activation can be stimulated via nanoparticlebased, artificial APCs using both liposomes and biocompatible polymers.[38] On the other hand, exosomes in the extracellular environment are biological nanoparticles (cell membrane vesicles) involved in intercellular communication with a\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (5 of 26)\nsize range of 30–100 nm that can act as natural carriers and biological modulators.[39] Therapeutic drugs, proteins, and/or nucleic acids can be loaded into isolated exosomes. Furthermore, DC-derived exosomes (Dexo) are biologically active and have contained the full complement of molecular machinery required for immunostimulation. Proteins such as integrin, intercellular adhesion molecules, lactadherin, and the tetraspanins CD63, CD81, and CD9 are embedded in the membranes of Dexo, equipping them with the ability to target, dock, and/ or fuse with recipient cells.[40] Promising antitumor responses have been elicited utilizing Dexo in both preclinical and earlyphase clinical trials. A recent phase II trial of Dexo loaded with interferon gamma (IFN-γ) was administered to patients with non-small-cell lung cancer.[41] Nanomedicines can also be utilized to decrease tumor microenvironment-mediated immunesuppressive signals, in addition to activating the immune system against tumor cells. Nanoparticles can be engineered for selective delivery of nucleotide-based therapies to regulate myeloid cell activity. Moreover, immune-checkpoint-blockade therapies can be combined with the delivery of immunostimulatory molecules.[42] A recent study demonstrated the successful use of ferumoxytol (iron oxide nanoparticles), an FDA-approved supplement for patients with iron deficiency, to switch TAMs from the immunosuppressive to proinflammatory phenotype, with antitumor and metastasis-restricting properties.[13b] Overall, a promising direction for immuno-oncology is unlocked in the targeting of myeloid cells for ablation or reprogramming to realize immune-stimulating therapies with elevated response rates."
    }, {
      "heading" : "2.3. Macrophages: Friends or Foes",
      "text" : "Over a century ago, Metschnikoff was the first to identify mono nuclear phagocytes, which are present in different amounts in various adult mammalian tissues.[43] Macrophages are present in most tissues, except the gut, in a steady state. These cells originate from primitive macrophages, which are established embryonically, before the appearance of hematopoietic stem and progenitor cells (HSPCs).[44] Macrophages that accumulate in the diseased tissues are derived from circulating blood monocytes. There are various mechanisms by which macrophages accumulate in diseased tissue: i) the release of monocytes from the bone marrow and spleen, ii) HSPC-mediated, elevated monocyte production, and iii) the amplification of local macrophages.[45] Macrophages play various vital roles in the defense of the host: They i) remove pathogens, ii) secrete cytokines, enzymes, and other factors that shape the inflammatory response, and iii) present antigens to lymphocytes for modulating adaptive immunity. Along with these beneficial effects, macrophages can also be detrimental, as evident from the tumor supportive activities of tumor stromal macrophages, i.e., TAMs. The amplification of progenitor cells that differentiate into macrophages is affected by tumors via the secretion of factors with long-reaching effects in the body.[46] This amplification ultimately creates a gradient for the attraction of circulating monocytes and TAM education to support tumor promotion, negatively impacting cancer prognosis.[47]\nMacrophages are divided into different subsets based on their anatomical location and function, e.g., alveolar macrophages (lung), osteoclasts (bone), and Kupffer cells (liver). Subsets of macrophages with diverse functions even coexist within the same organ, such as the spleen, where senescent erythrocytes are engulfed by the red pulp macrophages, while the white pulp macrophages are involved in immune response.[48] As for their inflammatory roles, macrophages are divided into two major groups: inflammatory (M1) macrophages, which are activated classically, and anti-inflammatory (M2) macrophages, also known as regulatory macrophages, which are activated to alleviate inflammation.[12] Via the production of proinflammatory cytokines, inducible nitric oxide synthase (iNOS), and reactive oxygen species (ROS), M1 macrophages potently counter invading pathogens upon stimulation by LPS or lipoteichoic acid or other danger signals (IFN-γ and tumor necrosis factors). M1 macrophages are seen either in the later stages of chronic inflammation or in the early phase of acute inflammation. Contributing to the inflammatory process, M1 macrophages secrete proinflammatory cytokines, such as CXCL9 and CXCL10 that attract natural killer and T cells.[49] The regulatory or antiinflammatory M2 macrophages, possessing restorative properties, are active in the later stages of acute infection via the production of inflammatory mediators, such as IL-10 and IL1receptor antagonist, along with arginase 1, that inhibit inflammation. Furthermore, through the secretion of cytokines like CCL-22, M2 macrophages attract Th2 cells and Tregs that act as supporting cells for maintaining homeostasis.[50] Interestingly, these subsets of macrophages are programmed as per their environment to act either as inflammatory or anti-inflammatory cells.\nAlong with the inhibition of the antitumor response, M2 TAMs enhance tumor growth and promote metastasis.[51] Poor prognosis for survival of patients is highly correlated with the presence and number of M2 TAMs. Reduced tumor growth and metastasis were observed in splenectomized mice having lower counts of relocating monocytes and, subsequently, a decreased number of TAMs.[45a] Macrophages are highly attracted and activated by the tumor microenvironment, which is characterized by hypoxia, dying cells, and chronic inflammation. Immune cells and tumor cells present in the TME secrete molecules, such as CCL-2, CSF-1, IL-10, and TGF-b, which influence monocyte recruitment and polarization to M2 TAM phenotype.[12] Impaired antigen presentation and inflammatory capabilities are generally associated with TAMs, while transcriptome analysis demonstrates that TAMs can adopt diverse roles based on the residing tumor. Epidermal growth factor (EGF) is produced by the invasive TAMs, along with proteases for extracellular matrix remodeling, paving the way for tumor metastasis.[52] Anti-inflammatory cytokines, such as IL-10, are produced by TAMs, along with CCL-22 for Tregs recruitment, followed by inflammatory response suppression. The growth of blood vessels and metastasis are promoted by angiogenic and metastatic TAMs via production of factors like VEGF.\nThe presence of stromal macrophages in human cancers is linked to aggressive disease and poor outcomes. The activation of colony-stimulating factor 1 receptor (CSF1R) by either CSF1 or IL-34 results in the recruitment of macrophages by tumors, while the CCL2 chemokine can also facilitate this\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (6 of 26)\nprocess.[53] Favorable prognosis in some tumor types, such as non-small-cell lung cancer, prostate, colorectal, and gastric cancers, has been associated with increased macrophage infiltration. Monocytes differentiate into macrophages and DCs once in a target tissue. Two types of circulating monocytes have been identified, i.e., classical inflammatory monocytes (CCR2HIGH) and nonclassical patrolling monocytes (CX3CR1HIGH).[54] The CCR2–CCL2 axis guides the inflammatory monocytes into tissues, while in tumors neoplastic cell survival and extravasation through VEGF and CSF1 production is promoted via recruitment of CCR2HIGH monocytes.[55] Via a CCL3dependent mechanism, CCR2HIGH monocytes promote the survival of metastatic cells. In response to the CXC3R1–CX3CL1 axis, CX3CR1HIGH monocytes patrol capillaries for scavenging particles and debris, while also recruiting NK cells to metastasis sites.[56] To generate antitumor immunity and suppress tumor growth, TH2-driven myeloid cells can either be reprogrammed or neutralized. Researchers have developed a variety of methods to accomplish these, along with combinatorial therapy of a chemotherapeutic (CTX) and/or radiotherapy (RT).[12,57]"
    }, {
      "heading" : "3. Tumor-Associated Macrophages: Effector Mechanisms and Targeting Strategies",
      "text" : "Tumor initiation and progression is promoted by TAMs via various mechanisms. Oncostatin M and IL10 (STAT3 activators) are secreted by M2-like TAMs and stimulate the proliferation of tumor cells, while cancer stem-like cells (CSC) are also maintained by STAT3.[58] To hinder CD4+ and CD8+ T cell effector function, immunosuppressive factors such as IL10 and TGFβ are produced by TAMs. Interestingly, TAMs\nactively play a vital role in tumor metastasis, angiogenesis, and vascular permeability via the production of VEGF, along with the type IV collagenases MMP2 and MMP9. Tumor growth and metastasis has been shown to be reduced via inhibition of TAM receptor CCR2 or CSF1R signaling, as CCL2 and CSF1 synthesized by tumor cells target TAM receptors to induce vascular permeability.[55,57d] Serum amyloid A3 targets TLR4 on TAMs, which results in the promotion of metastasis via creation of an environment for adhesion and invasion of tumor cells.[59] TAM recruitment also enhances the epithelial-mesenchymal transition (EMT), which is necessary for the invasiveness and metastasis of tumor cells.[60] Given the contributions of TAMs to tumor revival, growth, and metastasis, it becomes essential to devise TAM targeting strategies to inhibit cancer progression. Therapeutic agents, currently in clinical trials, that inhibit TAM recruitment, interfere with their survival, or re-educate the macrophages are shown in Figure 1."
    }, {
      "heading" : "3.1. Interference with TAM Survival or Inhibition of TAM Signaling Cascades",
      "text" : "Due to the importance of CSF1R signaling in macrophages, many potential clinical therapies have been developed to target CSF1R, mostly via small molecules, such as PLX3397, JNJ 40346527, PLX7486, ARRY 382, PLX7486, ARRY-382 and BLZ94.[61] Moreover, RG7155, IMC CS4, and FPA008 antiCSF1R mAbs are under intense investigation in different clinical trials.[57d,62] Depleting TAMs by stimulating their apoptosis may be of high therapeutic potential in limiting tumor development. Bisphosphonates can selectively inhibit proliferation, migration and invasion of macrophages.[63]\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (7 of 26)\nClodronate and zoledronic acid are currently being tested in various clinical trials for their potential anticancer effects in combination with chemotherapy and hormonal therapy.[64] Trabectedin (ET-743) is a tetrahydroisoquinoline alkaloid which targets mononuclear phagocytes, specifically by activating caspase-8, which, through Fas and TNF-related apoptosis inducing ligand receptors (TRAILRs), results in apoptosis.[65] Interestingly, due to the presence of a decoy receptor, neutrophils and T cells are protected from the cytotoxic effect of trabectedin. Furthermore, macrophages can phagocytose liposomal bisphosphonates, which is a potential drug for macrophage depletion and reduction in tumor progression.[66]\nIt is vital to introduce targeting agents that selectively ablate M2-like TAMs, since it is not ideal to target all the macrophages subtypes. In one approach, a peptide (M2pep) that selectively abrogates murine M2 macrophages and improves the survival rate of tumor-bearing mice has been described.[67] Moreover, in another approach, TAM survival was reduced via the targeting of its cell surface proteins. M2 macrophages in breast tumor tissues highly express legumain, whereas M1-like TAMs do not express the protein. In mice with metastatic cancers, CD8+ T cells can be stimulated for the selective ablation of M2 macrophages via a legumainbased DNA vaccine, resulting in blockages of metastasis and angiogenesis.[68] Another promising target specifically expressed on the surface of TAMs is scavenger receptor A (CD204). Targeting of CD204 with an anti-CD204 immunotoxin in mice with peritoneal ovarian cancer eradicated TAMs and hindered tumor progression.[69] Targeting murine or human IL4Rα/CD124 on TAMs with an RNA aptamer also resulted in CD8+ T cell infiltration, ultimately leading to TAM apoptosis.[70]"
    }, {
      "heading" : "3.2. Repression of Macrophage Recruitment to Tumors",
      "text" : "Peripheral monocytes are recruited to tumor sites via tumorderived chemokines CCL2 and CSF1. Specific to the tumor stage, various signals in the TME differentiate peripheral monocytes into the M1-like or M2-like phenotype. Hence, specifically targeting these signaling molecules can potentially inhibit the accumulation of TAMs in the TME.[12] In this regard, CCL2, which is produced by tumor cells, bone marrow osteoblasts, endothelial cells, and stromal cells plays an important role in tumorigenesis and metastasis.[55] CCL2 mimics the inflammatory response by acting as a chemotactic factor for the recruitment of macrophages that express the CCL2 receptor, CCR2, to the tumor site, resulting in proliferation and migration of tumor cells.[71] An anti CCL2 mAb, carlumab (CNTO 888), and PF 04136309, which is a small molecule inhibitor that targets CCR2, are the two main drugs currently being tested.[72] The proliferation, differentiation, and migration of macrophages are regulated by CSF1 and its receptor CSF1R; macrophage recruitment can be significantly reduced by blocking the CSF1/CSF1R axis. The CSF1R inhibitors PLX6134, GW2580 and PLX339 significantly reduce macrophage infiltration and augment CD8+ T cell responses.[73] Moreover, in MCF-7 breast cancer cell-xenografted mice, macrophage recruitment was suppressed through\nthe inhibition of CSF1 by either an antisense oligonucleotide or an anti-CSF1 antibody.[74] Remarkably, blockage of CSF1/ CSF1R binding also downregulates macrophage-produced MMP2, MMP12, and VEGFA, all of which are important in tumor invasion and angiogenesis.[57d] Furthermore, targeting the CSF1/CSF1R axis can re-educate M2-like TAMs to an M1-like phenotype. The CSF1R inhibitor, BLZ945, can specifically target M2-like TAMs in the mouse proneural glioblastoma multiforme model by reducing expression of genes, such as arginase 1 and CD206, while not affecting the overall number of TAMs.[75]"
    }, {
      "heading" : "3.3. Re-Educating Tumor-Associated Macrophages",
      "text" : "The plasticity of macrophages in the TME has been well established, as the cells respond to an alteration of molecules, including cytokines, chemokines, pattern recognition receptors and hormones.[76] Hence, re-educating tumor-promoting M2-like TAMs to a tumoricidal M1-like phenotype is a potential strategy for tumor eradication. M2-like TAMs promote an abnormal tumor vasculature, which leads to tumor progression and metastasis. TLR agonists polarize TAMs into M1-like cells with potential antitumor effects.[77] IMO 2055 (a TLR9 ligand), along with imiquimod and 852A (TLR7 ligands), is currently being tested as antitumoral agents in clinical trials.[78] TAMs also produce ligands, such as RANKL, LTα, LTβ, and LIGHT, that activate the NF-κB pathway, leading to the targeting of CXCL12 and VEGFC tumor-promoting genes via the LTβR, CD40, and RANK receptors.[79] Interestingly, the aforementioned pathway is the mechanistic basis for the repolarization of TAMs, which can be induced by CD40 blockage, which also leads to the upregulation of IL12, TNFα, and INF-γ. Copper N-(2-hydroxy acetophenone) glycinate (CuNG) activates p38 MAPK and ERK1/2 by stimulating reactive oxygen species formation, which leads to the production of IL12 and IFN-γ and the downregulation of TGFβ. Subsequently, CuNG leads to the repolarization of TAMs and potential antitumor effects.[80] Moreover, active microRNAs, such as miR-125, miR-155, and miR-378, are upregulated in M1 macrophages, while miR-9, miR-21, miR146, miR-147, miR-187, and miR-511-3p are expressed in M2 macrophages.[81] Overexpression of specifically miR-155 induces the repolarization of TAMs by enhancing the proinflammatory signaling regulated by NF-κB in response to TLR ligands and IFNs in macrophages.[82] The epigenetic profile of monocytes and macrophages can be modified via a specific inhibitor (TMP195) of class IIA HDACs, ultimately leading to altered CCL1 and CCL2 expression and a proinflammatory phenotype.[83] Interestingly, the efficacy and durability of carboplatin, paclitaxel, and anti-PD1 antibodies can be increased by TMP195-mediated macrophage modulation.[84] Furthermore, the expression of the pattern recognition receptor, MARCO (macrophage receptor with collagenous structure), by macrophages was shown to be linked to poor prognosis in breast cancer.[85] Targeting and neutralizing MARCO via antibodies elicited potent antitumor effects, and meanwhile also improved the efficacy of anti CTLA4 immunotherapy.[86] Hematopoietic cells express PI3Kγ, the absence of which has\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (8 of 26)\nbeen shown to correlate with an impaired recruitment of macrophages.[87] In a recent study, PI3Kγ was shown to be involved in the protumoral activities of TAMs, while its inhibition leads to TAM reprogramming and tumor inhibition.[88] The RNase-III enzyme, DICER, regulates the maturation of microRNAs (miRNAs), which are key regulators of transcription and translation.[89] Interestingly, inhibition of DICER in macrophages was demonstrated to affect the programming of TAM and stimulate tumor regression, along with an altered infiltration of immune cells.[90] The IFNγ–STAT1 “signature” was expressed by TAMs upon DICER inhibition, leading to TAM reprogramming and, ultimately, antitumor effects."
    }, {
      "heading" : "4. Nanomedical Approaches for Tackling Tumor-Associated Macrophages",
      "text" : "To overcome the resilient characteristics of the cancer immune environment, nanoparticles can be formulated to possess different sizes, shapes, and various surface modifications.[91] Considering the important role of TAMs in tumor immune suppression, various macrophage-targeting nanotheranostic formulations have been developed in recent years (Table 1). As mentioned in Section 3, various TAM-depleting and re-educating agents are currently in clinical development. However, side effects and a lack of specific targeting have limited their application in the clinic.[92] Compared with the traditional drug molecules, nanomedicine has several advantages[93]: traditional drugs are usually single molecules, while nanomedicine can aggregate several effectors; most traditional drugs have a single target and cannot easily enter cells, while nanomedicine can be designed to harbor multiple functions and can be designed to easily enter the targeted cells.[34,94] From this perspective, immuno-nanomedicines are more suitable for complex diseases such as cancer. Utilizing various strategies, nanomaterials loaded with therapeutic and targeting agents are developed to either deplete or re-educate TAMs (Figure 2). In the next section, we discuss the progress in the development of lipid, poly mer, inorganic, and carbon-based nanoformulations for TAM theranostics."
    }, {
      "heading" : "4.1. Lipid-Based Nanoparticles",
      "text" : "Liposomes have been widely and frequently used as drug carriers in nanomedicine. These particles are biocompatible in nature and possess the ability to encapsulate multiple compounds, such as hydrophobic drugs and hydrophilic agents, including DNA and siRNA. Zhang and Palmer described hemoglobin (Hb)-modified liposome uptake into macrophages via CD163 receptor-mediated endocytosis. With Hb on the surface of liposomes, the complex demonstrated specificity toward macrophages, while any agents can be loaded into the liposome to influence the function of the engulfing macrophages.[104] To overcome the rapid degradation of unprotected siRNA molecules, various delivery systems based on liposome have been developed. Leuschner et al. used CCR2 siRNA-loaded lipid nanoparticles to silence CCR2 mRNA, which is required for monocyte recruitment to tumors. The lipid nanoparticles\nare about 70–80 nm with a 95% siRNA entrapment efficiency, and the final ratio of lipid: siRNA was 7:1 w/w. To study the in vivo distribution of these nanoparticles, a near-infrared fluorochrome was used to label the siRNA. After intravenous administration, the liposome possessed a short circulation half-life of 8.1 min and accumulated in the spleen and bone marrow, where they delivered siRNA into the Ly6C-high monocytes, which are precursors of TAMs. Importantly, the liposome potently decreased the number of TAMs and inhibited tumor growth (Figure 3).[105] This formulation was the first nanotechnology-based design to inhibit the recruitment of monocytes. Similarly, to inhibit the recruitment of protumoral macrophages, clodronate-encapsulated liposomes (Clod-Lip) or bindarit were administered to mice with melanoma. ClodLip depleted TAMs and inhibited MCP-1 pharmacologically, thereby reducing macrophage recruitment.[106]\nA different category of drugs, whose toxic effect against TAMs has benefited from nanotechnology, are the bisphosphonates (BPs). Zoledronate (ZOL) is able to polarize TAMs toward a more inflammatory phenotype.[107] Sousa et al. studied J774 macrophages cultured in 4T1 cancer cell-conditioned medium (4T1CM) to assess liposome-encapsulated bisphosphonates. 4T1CM treatment led to macrophage modification toward M2 activation, while liposome-encapsulated ZOL enhanced the level of iNOS and TNF-α (proinflammatory signals).[107] Rajan et al. used PEGylated liposomal nanoparticle (PLN)-encapsulated alendronate to abrogate PLN-induced tumor growth through macrophage polarization.[108] The diameter of the PLNalendronate nanoparticle was 70–90 nm and the maximum drug loading efficiency was 4 to 5 mg mL−1. In another study, liposome-encapsulated clodronate was synthesized to target TAMs, resulting in a significant reduction of mesothelioma metastases. Liposomal clodronate also killed TAMs in mouse F9 teratocarcinoma and human A673 rhabdomyosarcoma tumor models. Combined with an anti-VEGF antibody, liposomal clodronate also significantly reduced blood vessel density and inhibited tumor growth.[66]\nAlupei et al. developed a long-circulating simvastatinloaded liposome (LCL-SIM) to treat melanoma. Compared to an equivalent concentration of SIM, LCL-SIM more strongly hindered melanoma progression. LCL-SIM significantly decreased TAM-mediated oxidative stress and the production of HIF-1α (provascularization signal) in tumors.[109] Some STAT3 inhibitors also have been identified to shift the phenotype of TAMs. Jose et al. manipulated cationic liposomes to codeliver curcumin and STAT3 siRNA to treat melanoma. The curcumin-loaded liposome–siRNA complex was prepared at a liposome:siRNA ratio of 10:1 w/w, with a final diameter of 192.6 ± 9.0 nm. This complex inhibited tumor growth, compared to either liposome-curcumin or STAT3 siRNA alone. Furthermore, mechanistic studies revealed that the antitumor activity was associated with suppressed STAT3 activity and reversion of M2-like polarization.[110]"
    }, {
      "heading" : "4.2. Polymer-Based Nanoparticles",
      "text" : "Polymer-based nanoparticles have been used in cancer therapy development for a long period of time because of their high\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (9 of 26)\ndrug-loading efficiency and ease of surface modification. Polymers such as N-(2-hydroxypropyl) methacrylamide (HPMA) can be used as drug carriers to avoid the toxicity associated with conventional chemotherapy. Zimel et al. found that HPMA copolymers can target TAMs in both primary and metastatic tumor microenvironments. HPMA was specifically taken up by CD11b+ TAMs at all primary and metastatic tumor sites and reversed TAM polarization.[125] Jung et al. generated 7C1 nanoparticles containing CX3CL1 siRNA to block monocyte recruitment and improve the efficiency of anti-VEGF therapy in colorectal cancer. They verified that the chemokine CX3CL1 was upregulated after anti-VEGF therapy, which contributed to the CX3CR1-dependent recruitment of Ly6Clo monocytes. These Ly6Clo monocytes abrogated the immunosuppressive microenvironment through recruiting neutrophils via CXCL5.[111] Their results showed that 7C1- CX3CL1 siRNA significantly reduced the CX3CL1 level in vivo, confirming the inhibition of monocyte recruitment to anti-VEGF-treated tumors. Taking\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (10 of 26)\nan alternative approach, Shen et al. inhibited Ly6Chi monocyte-recruitment by disturbing CCL2–CCR2 pathways. They developed monocyte-targeted, siCCR2-loaded cationic nanoparticles, which accumulated in monocytes and modified the tumor immunosuppressive microenvironment.[126] Elimination of TAMs by targeting their surface receptors has also been regarded as a promising method in cancer immunotherapy. For example, several polymers, including PLGA nanoparticles, have been decorated with mannose to target mannose receptors, which are highly expressed in TAMs. Niu et al. prepared mannose and acid-sensitive PEG modified PLGA nanoparticles coated with doxorubicin (DOX) and examined their uptake by TAMs. This group demonstrated that mannose and acid-sensitive PEG on the surface of the DOX-NPs significantly stimulated the accumulation of DOX in tumors and promoted the uptake of DOX into TAMs.[112] Zhan et al. conjugated a polysaccharide from Bletilla striata (BSP), which has an affinity for mannose receptors,\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (11 of 26)\nwith alendronate (ALN), a bisphosphonate compound. The ALN–BSP nanosystem selectively targeted macrophages and effectively eliminated TAMs.[95] Similarly, Wang et al. reported a bioresponsive polymeric complex (P3AB) that could selectively eliminate TAMs. Their complex used PEG, PLGA, and a peptide as a shell, with bisphosphonate–glucomannan conjugate as the core. P3AB polymeric complexes can be taken up by TAMs, leading to potent reductions in TAM viability.[114] In another study, Qian et al. developed TAM-targeting nanoparticles (M2NPs) loaded with anti-CSF-1R siRNA, with α-peptide (a scavenger receptor binding peptide) linked with M2pep (an M2 macrophage targeting peptide) on the particle surface. Compared to controls, the M2NP-loaded siRNA delivery system resulted in a significant elimination of TAMs. Furthermore, this system inhibited the production of IL-10 and TGF-β, while augmenting proinflammatory cytokine secretion (IL-12 and IFN-γ). Moreover, this delivery system downregulated the expression of PD-1 and Tim-3 on CD8+ T cells and enhanced their IFN-γ secretion.[113] Shi et al. used mannose-decorated PLGA to deliver ICG, NH4HCO3, and titanium dioxide to tumors.[127] Through mannose-mediated endocytosis, the PLGA nanoparticles accumulated in TAMs. Inside TAMs, NH4HCO3 produced CO2 and NH3 to disrupt the membrane of the liposome and endosome, releasing ICG and titanium dioxide into the cytoplasm to generate ROS (Figures 4 and 5). Other markers such as the folate receptor β (FR-β)[128] and scavenger receptor A (SR-A)[116] have been demonstrated to be exclusively expressed on macrophages present in tumor tissue.\nWith the aim to reduce the distribution of drugs in other organs and improve drug concentrations in targeted tumors, tumor microenvironment-responsive drug delivery systems\nhave been developed. Liu et al. designed redox/pH dual-responsive miR155-loaded nanoparticles using sPEG and GLC copolymers (sPEG/GLC/155). Attributed to the positive charge and the galactose moieties, the sPEG/GLC/155 was preferably taken up by macrophages. Meanwhile, the miRNA-loaded nanoparticles decreased TAM numbers and increased the number of activated T lymphocytes and NK cells inside tumors.[96] Wang et al. developed pH-responsive nanoparticles loaded with IL-12 for re-educating TAMs, with negligible systemic toxicity. Compared with free IL-12 in in vivo studies, the nanoparticles exhibited enhanced tumor accumulation, significantly extending the circulation half-life and enhancing therapeutic efficacy.[99] Huang et al. developed a nucleic acid drug delivery system by combining CpG oligonucleotides (ODN), anti-IL-10, with anti-IL-10 receptor ODN.[115] Galactosylated cationic dextran (gal-C-dextran) was used to load ODNs and target TAMs. Furthermore, PEG-histidine-modified alginate (PHA), a pHsensitive material, allowed the nanocarriers to preferentially release the agents in the acidic tumor microenvironment, while the galactosylated cationic dextran associated ODN could simultaneously target a galactose-type lectin overexpressed in TAMs, thereby stimulating the antitumor activities of TAMs.[115]\nM1 macrophages kill tumor cells by producing nitric oxide (NO), using l-arginine as a substrate. Kudo and Nagasaki proposed using PIC (polyion complex) micelles to generate a NOtriggered cancer immunotherapy.[129] These PIC micelles consisted of PEG-b-P(l-Arg) copolymers and chondroitin sulfate as polyanions. When treated with these nanoparticles, RAW264.7 macrophages produced significant levels of NO, inducing the apoptosis of tumor cells in a dose-dependent manner. In vivo, the micelles demonstrated a retention in the circulation and\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (12 of 26)\nsuppression of tumor progression with negligible toxicity. Moreover, self-assembled glyco-nanoparticles (glyco-NPs), composed of hydrophobic block polystyrene (PS) and a hydrophilic glycoblock (PR), have also been observed to re-educate M2 macrophages to the M1 phenotype.[97] The glyco-NPs were decorated with three sugars (d-galactopyranoside, α-mannopyranoside and l-fucopyranoside), which are associated with the expression of C-type lectins on macrophages. The size of the glyco-NPs, which could bind to macrophages at as low as 4 °C, varied from 34 to 36 nm. The glyco-NPs decreased the expression of CD206 and CD23 both in vitro and in vivo. Among various nanomaterials, DNA nanosystems are appealing materials owing to their designability and reduced host immune response. Zhang et al. found that tetrahedral\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (13 of 26)\nDNA nanostructures (TDNs) can inhibit the secretion of inflammatory cytokines and ROS in LPS-induced RAW264.7 cells via suppressing the MAPK pathway.[130] They prepared the TDNs with single-stranded DNA (ssDNA) molecules to form a nanoparticle with a diameter of 21.33 nm. To explore macrophages uptake of the nanoformulation, they loaded the construct with Cy3-labeled ssRNA and observed large amounts of Cy3-TDNs in the cytoplasm of macrophages. Another study reported that TDNs enter cells by the caveolin-dependent pathway.[131] These results suggest that TDNs are promising anti-inflammatory and antioxidant agents. Li et al. designed CpG motifs that self-assemble into DNA nanostructures.[132] They demonstrated that these DNA nanostructures are stable inside cells for several hours, and can be efficiently taken up\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (14 of 26)\nby macrophages, leading to the secretion of cytokines, such as IL-6, TNF-а, and IL-12.\nDespite the encouraging results achieved above, additional engineering to produce a more effective repolarization of TAMs is still needed. To achieve this goal, Rodell et al. developed a high throughput phenotypic screening assay to compare the efficiency of TAM re-education via 38 small molecules. One of these reagents, R848, a TLR7 and TLR8 agonist, potently drove the M1 phenotype in vitro. Thus, they developed R848-loaded β-cyclodextrin nanoparticles (CDNP-R848), which could target TAMs and reprogram them to the M1 phenotype. CDNP was prepared with succinyl-β-cyclodextrin and l-lysine via an amide bond, the particles having an approximate diameter of 30 nm and a relatively high drug loading efficiency of 10.39% w/w. The polarization efficiency of CDNPR848 was demonstrated in multiple tumor models and it was\nfound that CDNP-R848 could protect mice against tumor rechallenge. Furthermore, CDNP-R848 used in combination with anti-PD-1 led to improved immunotherapy response rates (Figures 6 and 7).[98]"
    }, {
      "heading" : "4.3. Inorganic Nanoparticles",
      "text" : "In addition to liposomes and polymers, inorganic nanoparticles with small sizes, large surface areas, and various surface modifications, have also attracted attention for TAM-based cancer immunotherapy. Tian et al. have designed multifunctional nanoparticles based on calcium bisphosphonate (CaBP-PEG) to deplete TAMs in vivo. With its effective TAM-depleting ability, the CaBP-PEG modulated the tumor microenvironment, exhibiting a potent inhibition of tumor growth (Figure 8).[100]\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (15 of 26)\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (16 of 26)\nMagnetic nanoparticles have been extensively studied in the context of cancer theranostics. Ferumoxytol elicits strong tumor growth inhibition through inhibiting the recruitment of monocytes to tumors and increasing the proportion of proinflammatory M1 macrophages within tumors. This polarization can induce fenton chemistry, resulting in the production of ROS for directly killing tumor cells. Furthermore, macrophages in the lung showed a significant loss of CD206 in the treatment group, which is indicative of M1 polarization. Ferumoxytol has also been demonstrated to prevent metastasis to the liver and lung in a macrophage-dependent manner (Figure 9).[13b] Taking a similar approach, da Silva et al. described a novel, iron-based proinflammatory niche. The heme, containing iron, released by RBCs at hemorrhagic areas, is taken up by TAMs. The heme or iron reprogrammed TAMs to the M1 phenotype, enabling them to directly kill tumor cells.[133] Li et al. prepared albumin-coated gold nanorods (AuNRs) loaded with paclitaxel (PTX). They found that the AuNRs can inhibit macrophages polarization toward the TAM phenotype via a thermal effect.[101] Gold nanoparticles decorated with the mucin-1 peptide (MUC-1) have also proven to promote M1 polarization by enhancing the release of proinflammation cytokines, such as TNF-ɑ and IL-12.[118] Dreaden et al. synthesized a novel gold nanoparticle conjugated with a macrolide, which accumulated in TAMs and afforded a selective cytotoxicity to cancer cells. Azithromycin, clarithromycin, and tricyclic ketolide, three macrolides, were bound to gold nanoparticles through a thiol-PEG linker. Preferential accumulation of the gold nanoparticles in TAMs was confirmed by cardioid immersion dark field scattering microscopy (DFSM), while a photothermal ablation response was engendered in AuNP-exposed TAMs.[117] In another study, M2 peptide (M2pep)-functionalized Au nanoparticles for VEGF siRNA delivery\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (17 of 26)\nwas designed for cancer immunotherapy (Figure 10).[102] AuNPs were decorated with M2pep and thiol-siRNA via a PEG linker with a mean diameter of 23.2 (±2.8) nm. Both RNAi–AuNPs and M2pep–RNAi–AuNPs were found to be stable in serum for over 48 h with only a 25% RNA release. Additionally, both nanoparticles were taken up by lung cancer cells, producing a robust disruption of VEGF expression. Compared to RNAi–AuNPs, M2pep– RNAi–AuNPs showed an increased accumulation in lung tumors, and a significant reduction (95%) of the number of TAMs. The arabinogalactan protein extracted from andrographis paniculata was combined with silver nanoparticles (SNP-ApAGP). The conjugate repolarized M2 macrophages by enhancing the release of proinflammatory cytokines, such as IL-12, TNF-α, and IL-6 along, with the generation of ROS and NO, both of which downregulate the release of anti-inflammatory cytokines, such as IL-4 and IL-10, as well as arginase-1 activity. Thus, SNP-ApAGP may be used to polarize TAMs to the M1 phenotype in cancer.[119]\nLeonard et al. found that porous silicon loaded with albumin– paclitaxel (MSV–nAb–PTX) shifted the macrophage behavior to the M1 phenotype, causing increased toxicity to tumor cells in comparison to nAb–PTX. The MSV–nAb–PTX also enhanced macrophage penetration into the depths of tumors.[120] Zinc oxide nanoparticles (ZnO NPs) are often used as a pH-dependent drug nanocarriers with the ability to stimulate their cel-\nlular uptake by cancer cells. Interestingly, Wang et al. verified that ZnO NPs can target macrophages; Dox-encapsulating ZnO NPs buttressed Dox-induced TAM polarization toward the M1-like phenotype.[121] Schoenenberger et al. studied the phenotype of macrophages exposed to nano- (<100 nm) and micro- (<5 µm) TiO2 nanoparticles (Figure 11). Interestingly, they found that only micro-TiO2 particles shifted macrophages to the M1 phenotype. However, no significant differences in cytokines were found when nano-TiO2 particles were exposed to macrophages. Together, many of the aforementioned studies have revealed that the size of nanoparticles is important in their effects on macrophage polarization, guiding the design of novel nanoparticles to treat inflammatory diseases such as cancer.[134]"
    }, {
      "heading" : "4.4. Carbon-Based Nanomaterials",
      "text" : "Carbon-based nanomaterials have been developed as a promising agents in nanomedicine due to their specific surface area, high drug loading efficiency, and diverse properties. Our group described gadolinium endohedral metallofullerenols (Gd@ C82(OH)22), polyhydroxylated C60 fullerene derivatives decorated with Gd, as functional agents in biological systems with low toxicity and good immunoregulatory effects. In one of our\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (18 of 26)\nstudies, Gd@C82(OH)22 modulated T cells and macrophages to secret TNF-α and IFN-γ to inhibit tumor growth.[135] Gd@ C82(OH)22, with a diameter of ≈157 nm, remained stable in complete medium for one month. In another investigation, our group took advantage of synchrotron-based scanning transmission X-ray microscopy (STXM) to examine the uptake and distribution of Gd@C82(OH)22 in macrophages. Gd@C82(OH)22 indeed entered macrophages to activate both NLRP3 inflammasomes and the TLRs–NF-κB pathway (Figure 12).[136] In addition, we used C60(OH)22/Gd@C82(OH)22-activated macrophages to suppress lung tumor metastasis.[122] After exposing the cells to C60(OH)22/Gd@C82(OH)22, the M1 polarization of macrophages was confirmed by cytokine secretion. Compared to C60(OH)22 alone, Gd@C82(OH)22 exhibited a stronger ability to enhance the expression of various inflammatory cytokines through activation of the NF-κB pathway (Figure 13).\nSo far, carbon nanotubes (CNTs) have been extensively examined for their special physicochemical properties. Their 1D structure makes them an ideal platform for biomedical applications.[137] In one of the earliest studies using CNTs to treat glioma, VanHandel et al. found most of CNTs were taken up by TAMs with no significant systemic toxicity in mice.[138] Furthermore, in a work utilizing a metastatic brain tumor mouse model, functionalized carbon nanotubes conjugated with CpG through disulfide bonds not only enhanced CpG uptake by TAMs but also resulted in the eradication of intracranial (i.c.) gliomas, protecting mice from tumor rechallenge, even at a low dose. Furthermore, increased retention of CNT–\nCpG was found in TLR-9 positive microglia, leading to the activation of NF-kB and AP-1 upon TLR stimulation.[123]\nYang et al. found that oxidized multiwalled carbon nanotubes (o-MWCNT) blocked the function of TAMs, decreased vessel density in tumors, and suppressed tumor progression and metastasis.[139] In addition, Oner et al. found no significant differences between MWCNT-exposed cells and single-walled carbon nanotube (SWCNT)-exposed cells, but, in contrast to SWCNT-exposed cells, MWCNT-exposed cells generated more hypomethylated gene promoters. Among the hypomethylated genes, STAT5A can induce M1 polarization through activating the NF-κB pathway and interferon regulatory factor 5.[140]\nGraphene (GO) is the youngest in the family of carbon nanomaterials. This carbon allotrope lattice has attracted considerable attention in cancer therapy, owing to its physicochemical properties and biocompatibility. Graphene significantly activates the TLR-mediated NF-kB pathway, enhances the secretion of IL-1a, TNF-α, and IL-10 cytokines as well as chemokines, such as MCP-1, MIP-1a, and RANTES. These inflammatory factors alter the morphology and function of naive macrophages. IL-10 inhibits macrophages from initiating inflammatory reactions, protecting macrophages from overactivation after graphene exposure.[141] Tao et al. used PEGand PEI-functionalized GO (GO-PEG-PEI) to deliver CpG. On the one hand, GO-PEG-PEI increased the level of proinflammatory cytokines and enhanced the function of CpG, while, on the other hand, GO-PEG-PEI, with its NIR absorbance,\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (19 of 26)\nincreased the immunostimulatory activity of CpG.[103] Ma et al. found that larger GO particles (750–1300 nm) stimulated M1 polarization more potently than smaller GO particles (50–350 nm). In contrast to the smaller GO moieties, larger GO particles can adsorb onto the macrophage membrane and robustly interact with Toll-like receptors, such as TLR2 and TLR4. As a result, larger GO particles more strongly activated the NF-κB pathway and greatly promoted M1 polarization in vitro and in vivo. In this study, they delineated the detailed mechanism of a size-dependent polarization of GO-exposed macrophages.[124]"
    }, {
      "heading" : "5. Imaging Tumor-Associated Macrophages with Nanoparticles",
      "text" : "Imaging the tumoral responses to cancer immuno-nanomedicines is critical to the design, development and application of effective and targeted treatments. Characterizing the therapeutic mechanism(s) of action, systemic immune effects, biodistribution, biosafety markers and other indicators of immune\nresponse can accelerate both preclinical and clinical trials.[142] Based on the type of information required, ImmunoPET, CT, MRI, optical, and their combinations, in the form of multimodality, imaging can be used in both basic research and clinical studies.[143]\nFor the exogenous labeling of immune, stem and other cells, nanomaterials have been used extensively. Imaging TAMs can be crucial for: i) extracting prognostic information, ii) guiding tumor biopsies, iii) analyzing variations in TAM concentrations within a single tumor or across metastases, iv) defining tumor margins, and v) quantifying treatment responses via mapping apoptosis-initiated macrophage recruitment.[145] TAMs can be labeled with MRI-compatible nanomaterials and PET imaging agents that are macrophage specific and have the potential of whole body quantification and imaging.[146] PET is a valuable technique, comprising a combination of structural and optical data for multiparameter imaging, and can be used to visualize various cancer-related parameters. In both benign and malignant nodes MRI can detect the tissue distribution of NPs that are internalized by macrophages.\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (20 of 26)\nClinical trials evaluating the practicability of ferumoxytol in predicting a patient’s response via imaging TAMs are currently ongoing.[147] Interestingly, unique MRI features are created due to the abnormal patterns of nanoparticle accumulation, which leads to an accurate determination of lymph node status.[148] Tissue macrophages present in lymph nodes, liver, spleen and bone marrow, along with circulating monocytes, mostly internalize long-circulating nanoparticles. It is vital to understand the underlying mechanisms of macrophage update of different NPs. The widely accepted mechanism of uptake is phagocytosis, which may vary based on the size and chemistry of NPs.[149] To achieve population specificity for nanoparticle uptake by different macrophage populations, various molecular markers have been utilized.[150] For example, nanomaterials typically label Ly-6Chi monocytes in mice more efficiently than their Ly-6Clo counterpart, a phenomenon which warrants further investigation.[150b] Recently, Kim et al. have developed 64Cu-labeled polyglucose nanoparticle (Macrin), which was pharmacokinetically optimized with the ability to quantify macrophages in tumors via PET.[144] Interestingly, more than 90% of Macrin was taken up by macrophages when analyzed by PET, high resolution in vivo confocal microscopy, and ex vivo tissue imaging (Figure 14). Furthermore, by using various chemotherapeutic and γ-irradiation regimens, Macrin was demonstrated to monitor macrophage response to neoadjuvant therapy, enabling the prediction of nanomedicine delivery (Figure 15). TAM-rich tumors, due to their enhanced permeability, demonstrated an elevated retention (>700%) of the nanotherapeutic (poly(d,l-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-PEG)), as compared to TAM-deficient tumors. Developing noninvasive methods for imaging TAMs holds great promise for patient selection into nanomedicine trials, as well as monitoring radiotherapy and immunotherapy treatment response."
    }, {
      "heading" : "6. Conclusion and Future Outlook",
      "text" : "Materials with immunomodulatory potential are being exploited for the development of cancer vaccines, expansion of T cells, checkpoint blocking, cytokine delivery, and TAM and MDSC modulation. As the utility of biomaterials in cancer immunotherapies accelerates, increasing efforts will focus on specifically modulating additional types of immune cells. The interface of TAMs, nanomedicine, and imaging are expected to soon become a promising step forward in the development of cancer immuno-nanomedicines. Patients’ specific responses, cancer type specificity, and robust targeting are the core characteristics that need improvement to achieve maximal clinical efficacy. High-throughput, library approaches, along with comprehensive phenotyping, will be crucial in the development of cutting edge materials with the potential to specifically target TAMs. Since the behavior of NPs may not always be the same in vitro and in vivo, extensive validation in animal models is vital for robust clinical translation. Stimulation of both the innate and adaptive immune system via judiciously designed\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (21 of 26)\ncancer immuno-nanomedicines will be important to enhance antitumor effects. The properties of nanoparticles such as size, shape, charge, material, surface functionalization, and choice of antigen and adjuvants will require extensive critical analysis to achieve precise delivery, improved stability, targeted biodistribution, favorable pharmacokinetics, and low systemic toxicity.\nThe interface of nanomaterials and immunology has enabled us to image and quantitate the progeny, distribution, kinetics and function of diverse, innate immune cells, especially macro phages. The internalization and processing of the coatings and cores of nanomaterials by different immune cells remain to be explored. The gaps in our understanding of nano–bio interactions, macrophage biology, optimal biological factors, and model cells are key areas for future consideration. To determine the intracellular toxicity of NPs and its therapeutic value, it will be important to explore the intracellular, chemical transformations of internalized nanoparticles. Nanoparticle risk assessment can be performed through the use of computational toxicology, high-throughput screening, “organ-on-a-chip” micro devices, intelligent testing strategies, and omics-based toxicology assessment methods. Due to the heterogeneity of the TME NP–cell interactions are also vital mechanisms to elucidate. Furthermore, tracking the intracellular trafficking of NPs is crucial, as it plays an important role in both therapeutic and imaging efficacy. Development of theranostic nanoparticles for TAMs needs more rigorous consideration, as the effects of photo dynamic therapy (PDT), photothermal therapy (PTT), sonodynamic therapy (SDT), and radiation therapy on the TME, and especially on TAMs, is only partially understood. In biological environments, NPs become bound by endogenous proteins that affect NPs’ absorption, distribution, metabolism and excretion (ADME) profile. Hence, elucidation of the toxicological pathways becomes important. Advanced analytical techniques have enabled us to explore the ADME profile of NPs, which can help in elucidating the effects of immuno-nanomedicines in detail. Furthermore, NPs with the ability to elucidate TAM concentrations in lesions at a whole-body level can lead to the development of effective TAM-targeted therapies. For the clinical translation of nanomaterials targeting TAMs, it is strongly recommended that the MIRIBEL (minimum information reporting in bio–nano\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (22 of 26)\nexperimental literature) standard be followed. Studies at the nano–bio interface require a thorough understanding of material and biological characteristics as well as the details of experimental protocols. Lastly, for the clinical translation of TAMs targeting immuno-nanomedicines, further work is required to explore novel immune cascades, therapeutic agents, and imaging techniques to provide more personalized and targeted effects.\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (23 of 26)"
    }, {
      "heading" : "Acknowledgements",
      "text" : "M.O. and M.G. contributed equally to this work. This research was supported by Ministry of Science and Technology of China (2016YFA0201600 and 2016YFE0133100), the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (11621505), the CAS Key Research Program for Frontier Sciences (QYZDJ-SSW-SLH022), the CAS interdisciplinary innovation team, and the National Science Fund for Distinguished Young Scholars (11425520).\nConflict of Interest The authors declare no conflict of interest.\nKeywords biomaterials, cancer immuno-nanomedicine, cancer immunotherapy, nanocarriers, tumor-associated macrophages\nReceived: December 25, 2018 Revised: February 7, 2019\nPublished online:\n[1] M. Vanneman, G. Dranoff, Nat. Rev. Cancer 2012, 12, 237. [2] L. Milling, Y. Zhang, D. J. Irvine, Adv. Drug Delivery Rev. 2017, 114,\n79. [3] A. Ribas, J. D. Wolchok, Science 2018, 359, 1350. [4] C. Lebbé, J. Weber, M. Maio, B. Neyns, K. Harmankaya, O. Hamid,\nS. O’day, C. Konto, L. Cykowski, M. McHenry, Ann. Oncol. 2014, 25, 2277. [5] W. Zou, J. D. Wolchok, L. Chen, Sci. Transl. Med. 2016, 8, 328rv4. [6] a) J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, C. L. Cowey,\nC. D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, N. Engl. J. Med. 2015, 373, 23; b) T. M. Allen, P. R. Cullis, Science 2004, 303, 1818. [7] a) J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat. Rev. Cancer 2017, 17, 20; b) D. Mittal, M. M. Gubin, R. D. Schreiber, M. J. Smyth, Curr. Opin. Immunol. 2014, 27, 16. [8] W. Jiang, C. A. Von Roemeling, Y. Chen, Y. Qie, X. Liu, J. Chen, B. Y. Kim, Nat. Biomed. Eng. 2017, 1, 0029. [9] W. Jiang, H. Yuan, C. K. Chan, C. A. Von Roemeling, Z. Yan, I. L. Weissman, B. Y. Kim, Nat. Rev. Drug Discovery 2017, 16, 369. [10] a) S. H. Kelly, L. S. Shores, N. L. Votaw, J. H. Collier, Adv. Drug Delivery Rev. 2017, 114, 3; b) M. Ovais, C. Chen, Nanomedicine 2018, 13, 2373; c) Y. Mi, C. C. Smith, F. Yang, Y. Qi, K. C. Roche, J. S. Serody, B. G. Vincent, A. Z. Wang, Adv. Mater. 2018, 30, 1706098. [11] M. F. Cuccarese, J. M. Dubach, C. Pfirschke, C. Engblom, C. Garris, M. A. Miller, M. J. Pittet, R. Weissleder, Nat. Commun. 2017, 8, 14293. [12] L. Cassetta, J. W. Pollard, Nat. Rev. Drug Discovery 2018, 17, 887. [13] a) H. Wang, D. J. Mooney, Nat. Mater. 2018, 17, 761;\nb) S. Zanganeh, G. Hutter, R. Spitler, O. Lenkov, M. Mahmoudi, A. Shaw, J. S. Pajarinen, H. Nejadnik, S. Goodman, M. Moseley, Nat. Nanotechnol. 2016, 11, 986. [14] S. R. Gordon, R. L. Maute, B. W. Dulken, G. Hutter, B. M. George, M. N. McCracken, R. Gupta, J. M. Tsai, R. Sinha, D. Corey, Nature 2017, 545, 495. [15] a) P. Zhao, W. Yin, A. Wu, Y. Tang, J. Wang, Z. Pan, T. Lin, M. Zhang, B. Chen, Y. Duan, Adv. Funct. Mater. 2017, 27, 1700403;\nb) L. Nuhn, S. De Koker, S. Van Lint, Z. Zhong, J. P. Catani, F. Combes, K. Deswarte, Y. Li, B. N. Lambrecht, S. Lienenklaus, Adv. Mater. 2018, 30, 1803397; c) C. Wang, Y. Ye, Q. Hu, A. Bellotti, Z. Gu, Adv. Mater. 2017, 29, 1606036. [16] D. S. Chen, I. Mellman, Immunity 2013, 39, 1. [17] C. T. Hagan, Y. B. Medik, A. Z. Wang, Adv. Cancer Res. 2018, 139,\n35. [18] G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, R. D. Schreiber, Nat.\nImmunol. 2002, 3, 991. [19] R. D. Schreiber, L. J. Old, M. J. Smyth, Science 2011, 331, 1565. [20] D. M. Pardoll, Nat. Rev. Cancer 2012, 12, 252. [21] Y. Yang, J. Clin. Invest. 2015, 125, 3335. [22] K. Palucka, J. Banchereau, Nat. Rev. Cancer 2012, 12, 265. [23] K. S. Ravichandran, Immunity 2011, 35, 445. [24] a) M. P. Chao, S. Jaiswal, R. Weissman-Tsukamoto, A. A. Alizadeh,\nA. J. Gentles, J. Volkmer, K. Weiskopf, S. B. Willingham, T. Raveh, C. Y. Park, Sci. Transl. Med. 2010, 2, 63ra94; b) V. A. Fadok, D. L. Bratton, D. M. Rose, A. Pearson, R. A. B. Ezekewitz, P. M. Henson, Nature 2000, 405, 85. [25] M. G. Morvan, L. L. Lanier, Nat. Rev. Cancer 2016, 16, 7. [26] a) S. Jaiswal, C. H. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao,\nR. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, Cell 2009, 138, 271; b) S. B. Willingham, J.-P. Volkmer, A. J. Gentles, D. Sahoo, P. Dalerba, S. S. Mitra, J. Wang, H. Contreras-Trujillo, R. Martin, J. D. Cohen, Proc. Natl. Acad. Sci. USA 2012, 109, 6662. [27] P. Sharma, J. P. Allison, Science 2015, 348, 56. [28] A. C. Anderson, Curr. Opin. Immunol. 2012, 24, 213. [29] J. Bubeník, Int. J. Oncol. 2004, 25, 487. [30] a) D. Marvel, D. I. Gabrilovich, J. Clin. Invest. 2015, 125, 3356;\nb) R. B. Holmgaard, D. Zamarin, Y. Li, B. Gasmi, D. H. Munn, J. P. Allison, T. Merghoub, J. D. Wolchok, Cell Rep. 2015, 13, 412. [31] S. K. Biswas, A. Mantovani, Nat. Immunol. 2010, 11, 889. [32] S. P. Kerkar, N. P. Restifo, Cancer Res. 2012, 72, 3125. [33] a) L. M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai,\nK. C. Reuter, M. Meng, D. Fritz, F. Vascotto, H. Hefesha, Nature 2016, 534, 396; b) H. B. Sager, P. Dutta, J. E. Dahlman, M. Hulsmans, G. Courties, Y. Sun, T. Heidt, C. Vinegoni, A. Borodovsky, K. Fitzgerald, Sci. Transl. Med. 2016, 8, 342ra80. [34] E. Blanco, H. Shen, M. Ferrari, Nat. Biotechnol. 2015, 33, 941. [35] S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak,\nW. C. Chan, Nat. Rev. Mater. 2016, 1, 16014. [36] a) P. Lizotte, A. Wen, M. Sheen, J. Fields, P. Rojanasopondist,\nN. Steinmetz, S. Fiering, Nat. Nanotechnol. 2016, 11, 295; b) A. V. Li, J. J. Moon, W. Abraham, H. Suh, J. Elkhader, M. A. Seidman, M. Yen, E.-J. Im, M. H. Foley, D. H. Barouch, Sci. Transl. Med. 2013, 5, 204ra130. [37] H. Yin, C.-Q. Song, J. R. Dorkin, L. J. Zhu, Y. Li, Q. Wu, A. Park, J. Yang, S. Suresh, A. Bizhanova, Nat. Biotechnol. 2016, 34, 328. [38] J. C. Sunshine, J. J. Green, Nanomedicine 2013, 8, 1173. [39] N. L. Syn, L. Wang, E. K.-H. Chow, C. T. Lim, B.-C. Goh, Trends\nBiotechnol. 2017, 35, 665. [40] C. Théry, M. Ostrowski, E. Segura, Nat. Rev. Immunol. 2009, 9,\n581. [41] B. Besse, M. Charrier, V. Lapierre, E. Dansin, O. Lantz,\nD. Planchard, T. Le Chevalier, A. Livartoski, F. Barlesi, A. Laplanche, OncoImmunology 2016, 5, e1071008. [42] Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng, Z. Liu, Nat. Commun. 2016, 7, 13193. [43] S. Gordon, Cell 2016, 166, 1065. [44] C. Schulz, E. G. Perdiguero, L. Chorro, H. Szabo-Rogers,\nN. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S. E. W. Jacobsen, J. W. Pollard, Science 2012, 336, 86. [45] a) V. Cortez-Retamozo, M. Etzrodt, A. Newton, P. J. Rauch, A. Chudnovskiy, C. Berger, R. J. Ryan, Y. Iwamoto, B. Marinelli, R. Gorbatov, Proc. Natl. Acad. Sci. USA 2012, 109, 2491;\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (24 of 26)\nb) F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J.-L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, Science 2009, 325, 612. [46] V. Cortez-Retamozo, M. Etzrodt, A. Newton, R. Ryan, F. Pucci, S. W. Sio, W. Kuswanto, P. J. Rauch, A. Chudnovskiy, Y. Iwamoto, Immunity 2013, 38, 296. [47] D. Hanahan, L. M. Coussens, Cancer Cell 2012, 21, 309. [48] F. Geissmann, S. Gordon, D. A. Hume, A. M. Mowat,\nG. J. Randolph, Nat. Rev. Immunol. 2010, 10, 453. [49] T. A. Wynn, A. Chawla, J. W. Pollard, Nature 2013, 496, 445. [50] T. F. Gajewski, H. Schreiber, Y.-X. Fu, Nat. Immunol. 2013, 14,\n1014. [51] T. Lawrence, G. Natoli, Nat. Rev. Immunol. 2011, 11, 750. [52] B.-Z. Qian, J. W. Pollard, Cell 2010, 141, 39. [53] Y. Komohara, M. Jinushi, M. Takeya, Cancer Sci. 2014, 105, 1. [54] F. Geissmann, S. Jung, D. R. Littman, Immunity 2003, 19, 71. [55] B.-Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion,\nE. A. Kaiser, L. A. Snyder, J. W. Pollard, Nature 2011, 475, 222. [56] R. N. Hanna, C. Cekic, D. Sag, R. Tacke, G. D. Thomas,\nH. Nowyhed, E. Herrley, N. Rasquinha, S. McArdle, R. Wu, Science 2015, 350, 985. [57] a) B. Ruffell, D. Chang-Strachan, V. Chan, A. Rosenbusch, C. M. Ho, N. Pryer, D. Daniel, E. S. Hwang, H. S. Rugo, L. M. Coussens, Cancer Cell 2014, 26, 623; b) S. L. Shiao, B. Ruffell, D. G. DeNardo, B. A. Faddegon, C. C. Park, L. M. Coussens, Cancer Immunol. Res. 2015, 3, 518; c) B. Ruffell, L. M. Coussens, Cancer Cell 2015, 27, 462; d) C. H. Ries, M. A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L. P. Pradel, F. Feuerhake, I. Klaman, Cancer Cell 2014, 25, 846; e) H. Eyob, H. A. Ekiz, Y. S. DeRose, S. E. Waltz, M. A. Williams, A. L. Welm, Cancer Discovery 2013, 3, 751. [58] a) H. Yu, M. Kortylewski, D. Pardoll, Nat. Rev. Immunol. 2007, 7, 41; b) P. Vlaicu, P. Mertins, T. Mayr, P. Widschwendter, B. Ataseven, B. Högel, W. Eiermann, P. Knyazev, A. Ullrich, BMC Cancer 2013, 13, 197. [59] S. Hiratsuka, A. Watanabe, Y. Sakurai, S. Akashi-Takamura, S. Ishibashi, K. Miyake, M. Shibuya, S. Akira, H. Aburatani, Y. Maru, Nat. Cell Biol. 2008, 10, 1349. [60] E. E. Mowers, M. N. Sharifi, K. F. Macleod, Oncogene 2017, 36, 1619. [61] a) S. J. Coniglio, E. Eugenin, K. Dobrenis, E. R. Stanley, B. L. West, M. H. Symons, J. E. Segall, Mol. Med. 2012, 18, 1; b) D. Yan, J. Kowal, L. Akkari, A. Schuhmacher, J. Huse, B. West, J. Joyce, Oncogene 2017, 36, 6049; c) W. D. Tap, Z. A. Wainberg, S. P. Anthony, P. N. Ibrahim, C. Zhang, J. H. Healey, B. Chmielowski, A. P. Staddon, A. L. Cohn, G. I. Shapiro, N. Engl. J. Med. 2015, 373, 428; d) B. Molena, P. Sfriso, F. Oliviero, E. Pagnin, A. Teramo, F. Lunardi, R. Stramare, A. Scanu, R. Nardacchione, L. Rubaltelli, Clin. Exp. Rheumatol. 2011, 29, 547. [62] a) NCT02526017, Study of Cabiralizumab in Combination with Nivolumab in Patients with Selected Advanced Cancers (FPA008003), https://clinicaltrials.gov/ct2/show/NCT02526017 (accessed: November 2018); b) NCT02471716, Study of Cabiralizumab in Patients with Pigmented Villonodular Synovitis/Diffuse Type Tenosynovial Giant Cell Tumor (FPA008-002), https://clinicaltrials. gov/ct2/show/NCT02471716 (accessed: November 2018); c) NCT01346358, A Study of IMC-CS4 in Subjects with Advanced Solid Tumors, https://clinicaltrials.gov/ct2/show/NCT01346358 (accessed: November 2018); d) NCT02265536, A Study of LY3022855 in Participants with Breast or Prostate Cancer, https:// clinicaltrials.gov/ct2/show/NCT02265536 (accessed: November 2018); e) NCT03153410, Pilot Study with CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients with Borderline Resectable Adenocarcinoma of the Pancreas, https://clinicaltrials. gov/ct2/show/NCT03153410 (accessed: November 2018).\n[63] a) V. Stresing, F. Daubiné, I. Benzaid, H. Mönkkönen, P. Clézardin, Cancer Lett. 2007, 257, 16; b) T. L. Rogers, I. Holen, J. Transl. Med. 2011, 9, 177. [64] a) M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Pöstlberger, C. Menzel, R. Jakesz, M. Seifert, M. Hubalek, V. Bjelic-Radisic, N. Engl. J. Med. 2009, 360, 679; b) NCT02347163, Pre-operative Zoledronate in Triple Negative Breast Cancer, https://clinicaltrials.gov/ct2/show/ NCT02347163 (accessed: November 2018); c) NCT02622607, Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients with Stage IIIB and IV Lung Cancer, https://clinicaltrials. gov/ct2/show/NCT02622607 (accessed: November 2018); d) NCT00127205, S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer, https://clinicaltrials. gov/ct2/show/NCT00127205 (accessed: November 2018); e) NCT00009945, Clodronate with or without Chemotherapy and/or Hormonal Therapy in Treating Women with Stage I or Stage II Breast Cancer, https://clinicaltrials.gov/ct2/show/NCT00009945 (accessed: November 2018); f) NCT00003232, Combination Chemotherapy in Treating Pain in Patients with Hormone Refractory Metastatic Prostate Cancer, https://clinicaltrials.gov/ ct2/show/NCT00003232 (accessed: November 2018). [65] G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, M. Liguori, E. Erba, S. Uboldi, M. Zucchetti, F. Pasqualini, Cancer Cell 2013, 23, 249. [66] S. Zeisberger, B. Odermatt, C. Marty, A. Zehnder-Fjällman, K. Ballmer-Hofer, R. Schwendener, Br. J. Cancer 2006, 95, 272. [67] M. Cieslewicz, J. Tang, L. Y. Jonathan, H. Cao, M. Zavaljevski, K. Motoyama, A. Lieber, E. W. Raines, S. H. Pun, Proc. Natl. Acad. Sci. USA 2013, 110, 15919. [68] Y. Luo, H. Zhou, J. Krueger, C. Kaplan, S.-H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, J. Clin. Invest. 2006, 116, 2132. [69] S. P. Bak, J. J. Walters, M. Takeya, J. R. Conejo-Garcia, B. L. Berwin, Cancer Res. 2007, 67, 4783. [70] F. Roth, C. Adriana, J. L. Vella, A. Zoso, L. Inverardi, P. Serafini, Cancer Res. 2012, 72, 1373. [71] a) D. E. Sanford, B. A. Belt, R. Z. Panni, A. Mayer, A. D. Deshpande, D. Carpenter, J. B. Mitchem, S. M. Plambeck-Suess, L. A. Worley, B. D. Goetz, Clin. Cancer Res. 2013, 19, 3404; b) R. D. Loberg, C. Ying, M. Craig, L. L. Day, E. Sargent, C. Neeley, K. Wojno, L. A. Snyder, L. Yan, K. J. Pienta, Cancer Res. 2007, 67, 9417. [72] a) S. K. Sandhu, K. Papadopoulos, P. C. Fong, A. Patnaik, C. Messiou, D. Olmos, G. Wang, B. J. Tromp, T. A. Puchalski, F. Balkwill, Cancer Chemother. Pharmacol. 2013, 71, 1041; b) L. Bonapace, M.-M. Coissieux, J. Wyckoff, K. D. Mertz, Z. Varga, T. Junt, M. Bentires-Alj, Nature 2014, 515, 130; c) K. J. Pienta, J.-P. Machiels, D. Schrijvers, B. Alekseev, M. Shkolnik, S. J. Crabb, S. Li, S. Seetharam, T. A. Puchalski, C. Takimoto, Invest. New Drugs 2013, 31, 760. [73] J. B. Mitchem, D. J. Brennan, B. L. Knolhoff, B. A. Belt, Y. Zhu, D. E. Sanford, L. Belaygorod, D. Carpenter, L. Collins, D. Piwnica-Worms, Cancer Res. 2013, 73, 1128. [74] P. Paulus, E. R. Stanley, R. Schäfer, D. Abraham, S. Aharinejad, Cancer Res. 2006, 66, 4349. [75] S. M. Pyonteck, L. Akkari, A. J. Schuhmacher, R. L. Bowman, L. Sevenich, D. F. Quail, O. C. Olson, M. L. Quick, J. T. Huse, V. Teijeiro, Nat. Med. 2013, 19, 1264. [76] Y. Lavin, D. Winter, R. Blecher-Gonen, E. David, H. Keren-Shaul, M. Merad, S. Jung, I. Amit, Cell 2014, 159, 1312. [77] H. Shime, M. Matsumoto, H. Oshiumi, S. Tanaka, A. Nakane, Y. Iwakura, H. Tahara, N. Inoue, T. Seya, Proc. Natl. Acad. Sci. USA 2012, 109, 2066. [78] a) S. Adams, L. Kozhaya, F. Martiniuk, T.-C. Meng, L. Chiriboga, L. Liebes, T. Hochman, N. Shuman, D. Axelrod, J. Speyer,\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (25 of 26)\nClin. Cancer Res. 2012, 18, 6748; b) NCT00319748, Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers, https://clinicaltrials. gov/ct2/show/NCT00319748 (accessed: November 2018); c) NCT00095160, Safety Study of an Immune Response Modifier in Patients with Refractory Solid Organ Tumors, https:// clinicaltrials.gov/ct2/show/NCT00095160 (accessed: November 2018); d) NCT00276159, Study of Immune Response Modifier in the Treatment of Hematologic Malignancies, https:// clinicaltrials.gov/ct2/show/NCT00276159 (accessed: November 2018); e) NCT00189332, Use of 852A in Metastatic Cutaneous Melanoma, https://clinicaltrials.gov/ct2/show/NCT00189332 (accessed: November 2018); f) NCT00091689, Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions, https://clinicaltrials.gov/ct2/show/ NCT00091689 (accessed: November 2018); g) A. Z. Dudek, C. Yunis, L. I. Harrison, S. Kumar, R. Hawkinson, S. Cooley, J. P. Vasilakos, K. S. Gorski, J. S. Miller, Clin. Cancer Res. 2007, 13, 7119. [79] S. K. Biswas, C. E. Lewis, J. Leukocyte Biol. 2010, 88, 877. [80] P. Chakraborty, S. Chatterjee, A. Ganguly, P. Saha, A. Adhikary,\nT. Das, M. Chatterjee, S. K. Choudhuri, J. Leukocyte Biol. 2012, 91, 609. [81] M. L. Squadrito, M. Etzrodt, M. De Palma, M. J. Pittet, Trends Immunol. 2013, 34, 350. [82] X. Cai, Y. Yin, N. Li, D. Zhu, J. Zhang, C.-Y. Zhang, K. Zen, J. Mol. Cell Biol. 2012, 4, 341. [83] M. Lobera, K. P. Madauss, D. T. Pohlhaus, Q. G. Wright, M. Trocha, D. R. Schmidt, E. Baloglu, R. P. Trump, M. S. Head, G. A. Hofmann, Nat. Chem. Biol. 2013, 9, 319. [84] J. L. Guerriero, A. Sotayo, H. E. Ponichtera, J. A. Castrillon, A. L. Pourzia, S. Schad, S. F. Johnson, R. D. Carrasco, S. Lazo, R. T. Bronson, Nature 2017, 543, 428. [85] A. Bergamaschi, E. Tagliabue, T. Sørlie, B. Naume, T. Triulzi, R. Orlandi, H. Russnes, J. Nesland, R. Tammi, P. Auvinen, J. Pathol. 2008, 214, 357. [86] a) A.-M. Georgoudaki, K. E. Prokopec, V. F. Boura, E. Hellqvist, S. Sohn, J. Östling, R. Dahan, R. A. Harris, M. Rantalainen, D. Klevebring, Cell Rep. 2016, 15, 2000; b) F. Li, J. V. Ravetch, Science 2011, 333, 1030. [87] E. Hirsch, V. L. Katanaev, C. Garlanda, O. Azzolino, L. Pirola, L. Silengo, S. Sozzani, A. Mantovani, F. Altruda, M. P. Wymann, Science 2000, 287, 1049. [88] M. M. Kaneda, K. S. Messer, N. Ralainirina, H. Li, C. J. Leem, S. Gorjestani, G. Woo, A. V. Nguyen, C. C. Figueiredo, P. Foubert, Nature 2016, 539, 437. [89] M. Ha, V. N. Kim, Nat. Rev. Mol. Cell Biol. 2014, 15, 509. [90] C. Baer, M. L. Squadrito, D. Laoui, D. Thompson, S. K. Hansen,\nA. Kiialainen, S. Hoves, C. H. Ries, C.-H. Ooi, M. De Palma, Nat. Cell Biol. 2016, 18, 790. [91] a) Z. Liu, W. Jiang, J. Nam, J. J. Moon, B. Y. Kim, Nano Lett. 2018, 18, 6655; b) G. T. Yu, L. Rao, H. Wu, L. L. Yang, L. L. Bu, W. W. Deng, L. Wu, X. Nan, W. F. Zhang, X. Z. Zhao, Adv. Funct. Mater. 2018, 28, 1801389. [92] C. Ngambenjawong, H. H. Gustafson, S. H. Pun, Adv. Drug Delivery Rev. 2017, 114, 206. [93] B. A. Aguado, J. C. Grim, A. M. Rosales, J. J. Watson-Capps, K. S. Anseth, Sci. Transl. Med. 2018, 10, eaam8645. [94] a) J. Jin, M. Ovais, C. Chen, Nano Today 2018, 22, 83; b) H. Chen, Z. Gu, H. An, C. Chen, J. Chen, R. Cui, S. Chen, W. Chen, X. Chen, X. Chen, Z. Chen, B. Ding, Q. Dong, Q. Fan, T. Fu, D. Hou, Q. Jiang, H. Ke, X. Jiang, G. Liu, S. Li, T. Li, Z. Liu, G. Nie, M. Ovais, D. Pang, N. Qiu, Y. Shen, H. Tian, C. Wang, H. Wang, Z. Wang, H. Xu, J.-F. Xu, X. Yang, S. Zhu, X. Zheng, X. Zhang, Y. Zhao, W. Tan, X. Zhang, Y. Zhao, Sci. China: Chem.\n2018, 61, 1503; c) Y. W. Noh, S. Y. Kim, J. E. Kim, S. Kim, J. Ryu, I. Kim, E. Lee, S. H. Um, Y. T. Lim, Adv. Funct. Mater. 2017, 27, 1605398. [95] X. D. Zhan, L. X. Jia, Y. M. Niu, H. X. Qi, X. P. Chen, Q. W. Zhang, J. F. Zhang, Y. T. Wang, L. Dong, C. M. Wang, Biomaterials 2014, 35, 10046. [96] L. L. Liu, H. Q. Yi, H. M. He, H. Pan, L. T. Cai, Y. F. Ma, Biomaterials 2017, 134, 166. [97] L. Su, W. Y. Zhang, X. L. Wu, Y. F. Zhang, X. Chen, G. W. Liu, G. S. Chen, M. Jiang, Small 2015, 11, 4191. [98] C. B. Rodell, S. P. Arlauckas, M. F. Cuccarese, C. S. Garris, R. Ahmed, R. H. Kohler, M. J. Pittet, R. Weissleder, Nat. Biomed. Eng. 2018, 2, 578. [99] Y. Wang, Y. X. Lin, S. L. Qiao, H. W. An, Y. Ma, Z. Y. Qiao, R. Rajapaksha, H. Wang, Biomaterials 2017, 112, 153. [100] L. Tian, X. Yi, Z. Dong, J. Xu, C. Liang, Y. Chao, Y. Wang, K. Yang, Z. Liu, ACS Nano 2018, 12, 11541. [101] D. D. Li, M. Zhang, F. Xu, Y. Z. Chen, B. F. Chen, Y. Chang, H. H. Zhong, H. Y. Jin, Y. Z. Huang, Acta Pharm. Sin. B 2018, 8, 74. [102] J. Conde, C. C. Bao, Y. Q. Tan, D. X. Cui, E. R. Edelman, H. S. Azevedo, H. J. Byrne, N. Artzi, F. R. Tian, Adv. Funct. Mater. 2015, 25, 4183. [103] Y. Tao, E. Ju, J. Ren, X. Qu, Biomaterials 2014, 35, 9963. [104] N. Zhang, A. F. Palmer, Biotechnol. Bioeng. 2012, 109, 823. [105] F. Leuschner, P. Dutta, R. Gorbatov, T. I. Novobrantseva,\nJ. S. Donahoe, G. Courties, K. M. Lee, J. I. Kim, J. F. Markmann, B. Marinelli, Nat. Biotechnol. 2011, 29, 1005. [106] S. Gazzaniga, A. I. Bravo, A. Guglielmotti, N. van Rooijen, F. Maschi, A. Vecchi, A. Mantovani, J. Mordoh, R. Wainstok, J. Invest. Dermatol. 2007, 127, 2031. [107] S. Sousa, S. Auriola, J. Monkkonen, J. Maatta, BMC Cancer 2015, 15, 4. [108] R. Rajan, M. K. Sabnani, V. Mavinkurve, H. Shmeeda, H. Mansouri, S. Bonkoungou, A. D. Le, L. M. Wood, A. A. Gabizon, N. M. La-Beck, J. Controlled Release 2018,271, 139. [109] M. C. Alupei, E. Licarete, L. Patras, M. Banciu, Cancer Lett. 2015, 356, 946. [110] A. Jose, S. Labala, K. M. Ninave, S. K. Gade, V. V. K. Venuganti, AAPS PharmSciTech 2018, 19, 166. [111] K. Jung, T. Heishi, O. F. Khan, P. S. Kowalski, J. Incio, N. N. Rahbari, E. Chung, J. W. Clark, C. G. Willett, A. D. Luster, S. H. Yun, R. Langer, D. G. Anderson, T. P. Padera, R. K. Jain, D. Fukumura, J. Clin. Invest. 2017, 127, 3039. [112] M. M. Niu, Y. W. Naguib, A. M. Aldayel, Y. C. Shi, S. D. Hursting, M. A. Hersh, Z. R. Cui, Mol. Pharmaceutics 2014, 11, 4425. [113] Y. Qian, S. Qiao, Y. F. Dai, G. Q. Xu, B. L. Dai, L. S. Lu, X. Yu, Q. M. Luo, Z. H. Zhang, ACS Nano 2017, 11, 9536. [114] Y. Wang, G. X. Guo, Y. X. Feng, H. Y. Long, D. L. Ma, C. H. Leung, L. Dong, C. M. Wang, J. Mater. Chem. B 2017, 5, 7307. [115] Z. Huang, Z. P. Zhang, Y. C. Jiang, D. C. Zhang, J. N. Chen, L. Dong, J. F. Zhang, J. Controlled Release 2012, 158, 286. [116] C. Neyen, A. Pluddemann, S. Mukhopadhyay, E. Maniati, M. Bossard, S. Gordon, T. Hagemann, J. Immunol. 2013, 190, 3798. [117] E. C. Dreaden, S. C. Mwakwari, L. A. Austin, M. J. Kieffer, A. K. Oyelere, M. A. El-Sayed, Small 2012, 8, 2819. [118] T. Mocan, C. Matea, F. Tabaran, C. Iancu, R. Orasan, L. Mocan, J. Cancer 2015, 6, 583. [119] M. R. C. Raja, V. V. Kumar, V. Srinivasan, S. Selvaraj, N. Radhakrishnan, R. Mukundan, S. Raghunandan, S. P. Anthony, S. K. Mahapatra, J. Mater. Chem. B 2017, 5, 3511. [120] F. Leonard, L. T. Curtis, M. J. Ware, T. Nosrat, X. W. Liu, K. Yokoi, H. B. Frieboes, B. Godin, Front. Immunol. 2017, 8, 693. [121] J. Wang, J. S. Lee, D. Kirn, L. Zhur, ACS Appl. Mater. Interfaces 2017, 9, 39971.\nAdv. Mater. 2019, 1808303\n© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1808303 (26 of 26)\n[122] J. L. Tang, Z. Y. Chen, B. Y. Sun, J. Q. Dong, J. Liu, H. G. Zhou, L. M. Wang, R. Bai, Q. Miao, Y. L. Zhao, C. Y. Chen, Y. Liu, Nanomedicine 2016, 12, 945. [123] H. T. Fan, I. Zhang, X. B. Chen, L. Y. Zhang, H. Q. Wang, A. Da Fonseca, E. R. Manuel, D. J. Diamond, A. Raubitschek, B. Badie, Clin. Cancer Res. 2012, 18, 5628. [124] J. Ma, R. Liu, X. Wang, Q. Liu, Y. N. Chen, R. P. Valle, Y. Y. Zuo, T. Xia, S. J. Liu, ACS Nano 2015, 9, 10498. [125] M. N. Zimel, C. B. Horowitz, V. K. Rajasekhar, A. B. Christ, X. Wei, J. Wu, P. M. Wojnarowicz, D. Wang, S. R. Goldring, P. E. Purdue, J. H. Healey, Mol. Cancer Ther. 2017, 16, 2701. [126] S. Shen, Y. Zhang, K.-G. Chen, Y.-L. Luo, J. Wang, Mol. Pharmaceutics 2018, 15, 3642. [127] C. Shi, T. Liu, Z. Guo, R. Zhuang, X. Zhang, X. Chen, Nano Lett. 2018, 18, 7330. [128] T. Nagai, M. Tanaka, Y. Tsuneyoshi, B. Xu, S. A. Michie, K. Hasui, H. Hirano, K. Arita, T. Matsuyama, Cancer Immunol. Immunother. 2009, 58, 1577. [129] S. Kudo, Y. Nagasaki, J. Controlled Release 2015, 217, 256. [130] Q. Zhang, S. Lin, S. Shi, T. Zhang, Q. Ma, T. Tian, T. Zhou, X. Cai,\nY. Lin, ACS Appl. Mater. Interfaces 2018, 10, 3421. [131] H. Lee, A. K. Lytton-Jean, Y. Chen, K. T. Love, A. I. Park,\nE. D. Karagiannis, A. Sehgal, W. Querbes, C. S. Zurenko, M. Jayaraman, Nat. Nanotechnol. 2012, 7, 389. [132] J. Li, H. Pei, B. Zhu, L. Liang, M. Wei, Y. He, N. Chen, D. Li, Q. Huang, C. Fan, ACS Nano 2011, 5, 8783. [133] M. C. da Silva, M. O. Breckwoldt, F. Vinchi, M. P. Correia, A. Stojanovic, C. M. Thielmann, M. Meister, T. Muley, A. Warth, M. Platten, M. W. Hentze, A. Cerwenka, M. U. Muckenthaler, Front. Immunol. 2017, 8, 1479. [134] A. D. Schoenenberger, A. Schipanski, V. Malheiro, M. Kucki, J. G. Snedeker, P. Wick, K. Maniura-Weber, ACS Biomater. Sci. Eng. 2016, 2, 908. [135] Y. Liu, F. Jiao, Y. Qiu, W. Li, F. Lao, G. Zhou, B. Sun, G. Xing, J. Dong, Y. Zhao, Z. Chai, C. Chen, Biomaterials 2009, 30, 3934 [136] Z. Y. Chen, Y. Liu, B. Y. Sun, H. Li, J. Q. Dong, L. J. Zhang, L. M. Wang, P. Wang, Y. L. Zhao, C. Y. Chen, Small 2014, 10, 2362. [137] A. Battigelli, C. Menard-Moyon, T. Da Ros, M. Prato, A. Bianco, Adv. Drug Delivery Rev. 2013, 65, 1899. [138] M. VanHandel, D. Alizadeh, L. Zhang, B. Kateb, M. Bronikowski, H. Manohara, B. Badie, J. Neuroimmunol. 2009, 208, 3.\n[139] M. Yang, J. Meng, X. Cheng, J. Lei, H. Guo, W. Zhang, H. Kong, H. Xu, Theranostics 2012, 2, 258. [140] D. Oner, M. Moisse, M. Ghosh, R. C. Duca, K. Poels, K. Luyts, E. Putzeys, S. M. Cokic, K. Van Landuyt, J. Vanoirbeek, D. Lambrechts, L. Godderis, P. H. M. Hoet, Mutagenesis 2017, 32, 181. [141] H. Zhou, K. Zhao, W. Li, N. Yang, Y. Liu, C. Chen, T. Wei, Biomaterials 2012, 33, 6933. [142] M. Mahmoudi, Trends Biotechnol. 2018, 36, 755. [143] N. J. Serkova, Front. Immunol. 2017, 8, 590. [144] H.-Y. Kim, R. Li, T. S. Ng, G. Courties, C. B. Rodell, M. Prytyskach,\nR. H. Kohler, M. Pittet, M. Nahrendorf, R. Weissleder, ACS Nano 2018, 12, 12015. [145] a) R. Weissleder, M. Nahrendorf, M. J. Pittet, Nat. Mater. 2014, 13, 125; b) S. Zanganeh, R. Spitler, G. Hutter, J. Q. Ho, M. Pauliah, M. Mahmoudi, Immunotherapy 2017, 9, 819. [146] a) E. J. Keliher, J. Yoo, M. Nahrendorf theranostic, J. S. Lewis, B. Marinelli, A. Newton, M. J. Pittet, R. Weissleder, Bioconjugate Chem. 2011, 22, 2383; b) H. Daldrup-Link, L. M. Coussens, OncoImmunology 2012, 1, 507. [147] NCT01770353, MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment, https://clinicaltrials.gov/ct2/show/NCT01770353 (accessed: November 2018). [148] a) M. G. Harisinghani, J. Barentsz, P. F. Hahn, W. M. Deserno, S. Tabatabaei, C. H. van de Kaa, J. de la Rosette, R. Weissleder, N. Engl. J. Med. 2003, 348, 2491; b) R. A. Heesakkers, G. J. Jager, A. M. Hövels, B. de Hoop, H. C. van den Bosch, F. Raat, J. A. Witjes, P. F. Mulders, C. H. van der Kaa, J. O. Barentsz, Radiology 2009, 251, 408. [149] a) I. Raynal, P. Prigent, S. Peyramaure, A. Najid, C. Rebuzzi, C. Corot, Invest. Radiol. 2004, 39, 56; b) C. D. Walkey, J. B. Olsen, H. Guo, A. Emili, W. C. Chan, J. Am. Chem. Soc. 2012, 134, 2139; c) B. Yameen, W. I. Choi, C. Vilos, A. Swami, J. Shi, O. C. Farokhzad, J. Controlled Release 2014, 190, 485; d) S. Behzadi, V. Serpooshan, W. Tao, M. A. Hamaly, M. Y. Alkawareek, E. C. Dreaden, D. Brown, A. M. Alkilany, O. C. Farokhzad, M. Mahmoudi, Chem. Soc. Rev. 2017, 46, 4218. [150] a) S. Gordon, F. O. Martinez, Immunity 2010, 32, 593; b) A. Sica, A. Mantovani, J. Clin. Invest. 2012, 122, 787.\nAdv. Mater. 2019, 1808303"
    } ],
    "references" : [ {
      "title" : "Proc",
      "author" : [ "H. Shime", "M. Matsumoto", "H. Oshiumi", "S. Tanaka", "A. Nakane", "Y. Iwakura", "H. Tahara", "N. Inoue", "T. Seya" ],
      "venue" : "Natl. Acad. Sci. USA 2012, 109",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2066
    }, {
      "title" : "WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim",
      "author" : [ "a) S. Adams", "L. Kozhaya", "F. Martiniuk", "T.-C. Meng", "L. Chiriboga", "L. Liebes", "T. Hochman", "N. Shuman", "D. Axelrod", "J. Speyer", "Adv. Mater" ],
      "venue" : "Cancer Res",
      "citeRegEx" : "78",
      "shortCiteRegEx" : "78",
      "year" : 2019
    }, {
      "title" : "N",
      "author" : [ "S. Gazzaniga", "A.I. Bravo", "A. Guglielmotti" ],
      "venue" : "van Rooijen, F. Maschi, A. Vecchi, A. Mantovani, J. Mordoh, R. Wainstok, J. Invest. Dermatol. 2007, 127",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2031
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "TLR agonists polarize TAMs into M1-like cells with potential antitumor effects.[77] IMO 2055 (a TLR9 ligand), along with imiquimod and 852A (TLR7 ligands), is currently being tested as antitumoral agents in clinical trials.",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 1,
      "context" : "[77] IMO 2055 (a TLR9 ligand), along with imiquimod and 852A (TLR7 ligands), is currently being tested as antitumoral agents in clinical trials.[78] TAMs also produce ligands, such as RANKL, LTα, LTβ, and LIGHT, that activate the NF-κB pathway, leading to the targeting of CXCL12 and VEGFC tumor-promoting genes via the LTβR, CD40, and RANK receptors.",
      "startOffset" : 144,
      "endOffset" : 148
    }, {
      "referenceID" : 2,
      "context" : "ClodLip depleted TAMs and inhibited MCP-1 pharmacologically, thereby reducing macrophage recruitment.[106] A different category of drugs, whose toxic effect against TAMs has benefited from nanotechnology, are the bisphosphonates (BPs).",
      "startOffset" : 101,
      "endOffset" : 106
    } ],
    "year" : 2019,
    "abstractText" : "DOI: 10.1002/adma.201808303 cancer immunotherapies has taken several years to develop, but key advancements in the basics of cancer immunology and translational immunotherapy have now resulted in treatments having noteworthy therapeutic effects in clinical trials.[2] These treatments include the injection of autologous, tumor-directed T cells, as a form of adoptive cell therapy (ACT), checkpoint blockade, and antibodies blocking the inhibitory receptors cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1, or its counter-receptors PD-L1/PDL2).[3] Interestingly, ACT therapy can elicit a thorough eradication of detectable tumor burden in patients with advanced metastatic melanoma or hematologic cancer, with long-term responses. In 20% of advanced melanoma patients, a fully humanized anti-CTLA-4 antibody (ipilimumab) produced a complete response lasting for a decade.[4] In a variety of cancers (lung, prostate, breast, ovarian, and head and neck and colorectal) treatment with PD-1 blocking antibodies demonstrated potent responses.[5] The combination therapies of anti-CTLA-4 and anti-PD1 has led to even more significant responses in melanoma patients due to the complementary modes of action of the two target proteins.[6] Sufficient activation of the immune system by a cancer immunotherapy to affect a potent response is a slow process, especially in patients with advanced cancer.[7] A patient’s specific immune status, genetics, tumor type, and environmental exposure can all affect the outcome of cancer immunotherapy.[8] Nanoparticles, due to their diverse physical and chemical properties, can be utilized as potential immunomodulating agents.[10] However, the specific toxicity associated with immunotherapies, along with the low response rate, are two important obstacles to consider in the preclinical and clinical development of cancer immuno-nanomedicines.[9] Myeloid-derived macrophages and tissue-resident macrophages, collectively known as tumor-associated macrophages (TAMs), are present in the tumor microenvironment (TME).[11] Upon interaction with a tumor, TAMs can become immunosuppressed and behave as regenerative macrophages. The origin (either recruitment from peripheral sites outside the CNS or tissue-resident cell invasion) composition and phenotypic evolution of TAMs during tumorigenesis are currently under intense investigation.[12] Based on the cellular context, TAMs can exhibit tumoricidal M1 or regenerative M2 phenotypic activation states; Advances in the field of nanotechnology together with an increase understanding of tumor immunology have paved the way for the development of more personalized cancer immuno-nanomedicines. Nanovehicles, due to their specific physicochemical properties, are emerging as key translational moieties in tackling tumor-promoting, M2-like tumor-associated macrophages (TAMs). Cancer immunonanomedicines target TAMs primarily by blocking M2-like TAM survival or affecting their signaling cascades, restricting macrophage recruitment to tumors and re-educating tumor-promoting M2-like TAMs to the tumoricidal, M1-like phenotype. Here, the TAM effector mechanisms and strategies for targeting TAMs are summarized, followed by a focus on the mechanistic considerations in the development of novel immuno-nanomedicines. Furthermore, imaging TAMs with nanoparticles so as to forecast a patient’s clinical outcome, describing treatment options, and observing therapy responses is also discussed. At present, strategies that target TAMs are being investigated not only at the basic research level but also in early clinical trials. The significance of TAM-targeting biomaterials is highlighted, with the goal of facilitating future clinical translation. Tumor-Associated Macrophages",
    "creator" : "Adobe InDesign CS6 (Macintosh)"
  }
}